1
|
Belzer A, Pach J, Mortlock RD, Clune J, Olino K, Sznol M, Bhatia A, Burtness B, Christensen S, Leventhal JS. Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability. JAAD Int 2023; 11:174-175. [PMID: 37252181 PMCID: PMC10213716 DOI: 10.1016/j.jdin.2023.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
Affiliation(s)
- Annika Belzer
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
| | - Jolanta Pach
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
| | - Ryland D. Mortlock
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
| | - James Clune
- Department of Plastic Surgery, Yale School of Medicine, New Haven, Connecticut
| | - Kelly Olino
- Department of Surgical Oncology, Yale School of Medicine, New Haven, Connecticut
| | - Mario Sznol
- Department of Internal Medicine and Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
| | - Aarti Bhatia
- Department of Internal Medicine and Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
| | - Barbara Burtness
- Department of Internal Medicine and Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
| | - Sean Christensen
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
| | | |
Collapse
|
2
|
Adusumilli G, Faizy TD, Christensen S, Mlynash M, Loh Y, Albers GW, Lansberg MG, Fiehler J, Heit JJ. Comprehensive Venous Outflow Predicts Functional Outcomes in Patients with Acute Ischemic Stroke Treated by Thrombectomy. AJNR Am J Neuroradiol 2023; 44:675-680. [PMID: 37202117 PMCID: PMC10249690 DOI: 10.3174/ajnr.a7879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 04/22/2023] [Indexed: 05/20/2023]
Abstract
BACKGROUND AND PURPOSE Cortical venous outflow has emerged as a robust measure of collateral blood flow in acute ischemic stroke. The addition of deep venous drainage to this assessment may provide valuable information to further guide the treatment of these patients. MATERIALS AND METHODS We performed a multicenter retrospective cohort study of patients with acute ischemic stroke treated by thrombectomy between January 2013 and January 2021. The internal cerebral veins were scored on a scale of 0-2. This metric was combined with existing cortical vein opacification scores to create a comprehensive venous outflow score from 0 to 8 and stratify patients as having favorable-versus-unfavorable comprehensive venous outflow. Outcome analyses were primarily conducted using the Mann-Whitney U and χ2 tests. RESULTS Six hundred seventy-eight patients met the inclusion criteria. Three hundred fifteen were stratified as having favorable comprehensive venous outflow (mean age, 73 years; range, 62-81 years; 170 men), and 363, as having unfavorable comprehensive venous outflow (mean age, 77 years; range, 67-85 years; 154 men). There were significantly higher rates of functional independence (mRS 0-2; 194/296 versus 37/352, 66% versus 11%, P < .001) and excellent reperfusion (TICI 2c/3; 166/313 versus 142/358, 53% versus 40%, P < .001) in patients with favorable comprehensive venous outflow. There was a significant increase in the association of mRS with the comprehensive venous outflow score compared with the cortical vein opacification score (-0.74 versus -0.67, P = .006). CONCLUSIONS A favorable comprehensive venous profile is strongly associated with functional independence and excellent postthrombectomy reperfusion. Future studies should focus on patients with venous outflow status that is discrepant with the eventual outcome.
Collapse
Affiliation(s)
- G Adusumilli
- From the Department of Radiology (G.A.), Massachusetts General Hospital, Boston, Massachusetts
| | - T D Faizy
- Department of Neuroradiology (T.D.F., J.F.), University of Hamburg-Eppendorf, Hamburg, Germany
| | | | - M Mlynash
- Stanford Stroke Center (S.C., M.M., G.W.A., M.G.L.)
| | - Y Loh
- Comprehensive Stroke Center (Y.L.), Swedish Neuroscience Institute, Seattle, Washington
| | - G W Albers
- Stanford Stroke Center (S.C., M.M., G.W.A., M.G.L.)
| | - M G Lansberg
- Stanford Stroke Center (S.C., M.M., G.W.A., M.G.L.)
| | - J Fiehler
- Department of Neuroradiology (T.D.F., J.F.), University of Hamburg-Eppendorf, Hamburg, Germany
| | - J J Heit
- Department of Radiology (J.J.H.), Stanford University, Stanford, California
| |
Collapse
|
3
|
Ranapurwala SI, Alam IZ, Pence BW, Carey TS, Christensen S, Clark M, Chelminski PR, Wu LT, Greenblatt LH, Korte JE, Wolfson M, Douglas HE, Bowlby LA, Capata M, Marshall SW. Development and validation of an electronic health records-based opioid use disorder algorithm by expert clinical adjudication among patients with prescribed opioids. Pharmacoepidemiol Drug Saf 2023; 32:577-585. [PMID: 36585827 PMCID: PMC10073250 DOI: 10.1002/pds.5591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2022] [Revised: 12/05/2022] [Accepted: 12/22/2022] [Indexed: 01/01/2023]
Abstract
BACKGROUND In the US, over 200 lives are lost from opioid overdoses each day. Accurate and prompt diagnosis of opioid use disorders (OUD) may help prevent overdose deaths. However, international classification of disease (ICD) codes for OUD are known to underestimate prevalence, and their specificity and sensitivity are unknown. We developed and validated algorithms to identify OUD in electronic health records (EHR) and examined the validity of OUD ICD codes. METHODS Through four iterations, we developed EHR-based OUD identification algorithms among patients who were prescribed opioids from 2014 to 2017. The algorithms and OUD ICD codes were validated against 169 independent "gold standard" EHR chart reviews conducted by an expert adjudication panel across four healthcare systems. After using 2014-2020 EHR for validating iteration 1, the experts were advised to use 2014-2017 EHR thereafter. RESULTS Of the 169 EHR charts, 81 (48%) were reviewed by more than one expert and exhibited 85% expert agreement. The experts identified 54 OUD cases. The experts endorsed all 11 OUD criteria from the Diagnostic and Statistical Manual of Mental Disorders-5, including craving (72%), tolerance (65%), withdrawal (56%), and recurrent use in physically hazardous conditions (50%). The OUD ICD codes had 10% sensitivity and 99% specificity, underscoring large underestimation. In comparison our algorithm identified OUD with 23% sensitivity and 98% specificity. CONCLUSIONS AND RELEVANCE This is the first study to estimate the validity of OUD ICD codes and develop validated EHR-based OUD identification algorithms. This work will inform future research on early intervention and prevention of OUD.
Collapse
Affiliation(s)
- Shabbar I. Ranapurwala
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, North Carolina, USA
- Injury Prevention Research Center, UNC, Chapel Hill, North Carolina, USA
| | - Ishrat Z. Alam
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, North Carolina, USA
- Injury Prevention Research Center, UNC, Chapel Hill, North Carolina, USA
| | - Brian W. Pence
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, North Carolina, USA
- Injury Prevention Research Center, UNC, Chapel Hill, North Carolina, USA
| | - Timothy S. Carey
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, North Carolina, USA
- North Carolina Translational and Clinical Sciences Institute, School of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA
- Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA
| | - Sean Christensen
- Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Marshall Clark
- North Carolina Translational and Clinical Sciences Institute, School of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA
| | - Paul R. Chelminski
- Division of General Internal Medicine and Clinical Epidemiology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA
| | - Li-Tzy Wu
- Department of Psychiatry and Behavioral Sciences, School of Medicine, Duke University, Durham, North Carolina, USA
- Department of Medicine, School of Medicine, Duke University, Durham, North Carolina, USA
| | - Lawrence H. Greenblatt
- Department of Medicine, School of Medicine, Duke University, Durham, North Carolina, USA
| | - Jeffrey E. Korte
- Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Mark Wolfson
- Department of Social Medicine, Population, and Public Health, School of Medicine, University of California, Riverside, California, USA
| | - Heather E. Douglas
- Department of Psychiatry and Behavioral Medicine, School of Medicine, Wake Forest University, Winston-Salem, North Carolina, NC, USA
| | - Lynn A. Bowlby
- Department of Medicine, School of Medicine, Duke University, Durham, North Carolina, USA
| | - Michael Capata
- Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Stephen W. Marshall
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, North Carolina, USA
- Injury Prevention Research Center, UNC, Chapel Hill, North Carolina, USA
| |
Collapse
|
4
|
Stergiou N, Wuensche TE, Schreurs M, Mes I, Verlaan M, Kooijman EJM, Windhorst AD, Helboe L, Vergo S, Christensen S, Asuni AA, Jensen A, Van Dongen GAMS, Bang-Andersen B, Vugts DJ, Beaino W. Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody. Eur J Nucl Med Mol Imaging 2023; 50:1306-1317. [PMID: 36635462 PMCID: PMC10027647 DOI: 10.1007/s00259-023-06109-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 01/05/2023] [Indexed: 01/14/2023]
Abstract
PURPOSE The recent conditional FDA approval of Aducanumab (Adu) for treating Alzheimer's disease (AD) and the continued discussions around that decision have increased interest in immunotherapy for AD and other brain diseases. Reliable techniques for brain imaging of antibodies may guide decision-making in the future but needs further development. In this study, we used 89Zr-immuno-PET to evaluate the targeting and distribution of a bispecific brain-shuttle IgG based on Adu with transferrin receptor protein-1 (TfR1) shuttling mechanism, mAbAdu-scFab8D3, designated Adu-8D3, as a candidate theranostic for AD. We also validated the 89Zr-immuno-PET platform as an enabling technology for developing new antibody-based theranostics for brain disorders. METHODS Adu, Adu-8D3, and the non-binding control construct B12-8D3 were modified with DFO*-NCS and radiolabeled with 89Zr. APP/PS1 mice were injected with 89Zr-labeled mAbs and imaged on days 3 and 7 by positron emission tomography (PET). Ex vivo biodistribution was performed on day 7, and ex vivo autoradiography and immunofluorescence staining were done on brain tissue to validate the PET imaging results and target engagement with amyloid-β plaques. Additionally, [89Zr]Zr-DFO*-Adu-8D3 was evaluated in 3, 7, and 10-month-old APP/PS1 mice to test its potential in early stage disease. RESULTS A 7-fold higher brain uptake was observed for [89Zr]Zr-DFO*-Adu-8D3 compared to [89Zr]Zr-DFO*-Adu and a 2.7-fold higher uptake compared to [89Zr]Zr-DFO*-B12-8D3 on day 7. Autoradiography and immunofluorescence of [89Zr]Zr-DFO*-Adu-8D3 showed co-localization with amyloid plaques, which was not the case with the Adu and B12-8D3 conjugates. [89Zr]Zr-DFO*-Adu-8D3 was able to detect low plaque load in 3-month-old APP/PS1 mice. CONCLUSION 89Zr-DFO*-immuno-PET revealed high and specific uptake of the bispecific Adu-8D3 in the brain and can be used for the early detection of Aβ plaque pathology. Here, we demonstrate that 89Zr-DFO*-immuno-PET can be used to visualize and quantify brain uptake of mAbs and contribute to the evaluation of biological therapeutics for brain diseases.
Collapse
Affiliation(s)
- N Stergiou
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - T E Wuensche
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - M Schreurs
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - I Mes
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - M Verlaan
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - E J M Kooijman
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - A D Windhorst
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - L Helboe
- H. Lundbeck A/S, Copenhagen, Denmark
| | - S Vergo
- H. Lundbeck A/S, Copenhagen, Denmark
| | | | - A A Asuni
- H. Lundbeck A/S, Copenhagen, Denmark
| | - A Jensen
- H. Lundbeck A/S, Copenhagen, Denmark
| | - G A M S Van Dongen
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | | | - D J Vugts
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - W Beaino
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands.
| |
Collapse
|
5
|
Cecchi M, Adachi M, Basile A, Buhl DL, Chadchankar H, Christensen S, Christian E, Doherty J, Fadem KC, Farley B, Forman MS, Honda S, Johannesen J, Kinon BJ, Klamer D, Marino MJ, Missling C, O'Donnell P, Piser T, Puryear CB, Quirk MC, Rotte M, Sanchez C, Smith DG, Uslaner JM, Javitt DC, Keefe RSE, Mathalon D, Potter WZ, Walling DP, Ereshefsky L. Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers. Schizophr Res 2023; 254:178-189. [PMID: 36921403 DOI: 10.1016/j.schres.2023.02.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Revised: 11/23/2022] [Accepted: 02/10/2023] [Indexed: 03/18/2023]
Abstract
OBJECTIVE Complexity and lack of standardization have mostly limited the use of event-related potentials (ERPs) and quantitative EEG (QEEG) biomarkers in drug development to small early phase trials. We present results from a clinical study on healthy volunteers (HV) and patients with schizophrenia (SZ) that assessed test-retest, group differences, variance, and correlation with functional assessments for ERP and QEEG measures collected at clinical and commercial trial sites with standardized instrumentation and methods, and analyzed through an automated data analysis pipeline. METHODS 81 HV and 80 SZ were tested at one of four study sites. Subjects were administered two ERP/EEG testing sessions on separate visits. Sessions included a mismatch negativity paradigm, a 40 Hz auditory steady-state response paradigm, an eyes-closed resting state EEG, and an active auditory oddball paradigm. SZ subjects were also tested on the Brief Assessment of Cognition (BAC), Positive and Negative Syndrome Scale (PANSS), and Virtual Reality Functional Capacity Assessment Tool (VRFCAT). RESULTS Standardized ERP/EEG instrumentation and methods ensured few test failures. The automated data analysis pipeline allowed for near real-time analysis with no human intervention. Test-retest reliability was fair-to-excellent for most of the outcome measures. SZ subjects showed significant deficits in ERP and QEEG measures consistent with published academic literature. A subset of ERP and QEEG measures correlated with functional assessments administered to the SZ subjects. CONCLUSIONS With standardized instrumentation and methods, complex ERP/EEG testing sessions can be reliably performed at clinical and commercial trial sites to produce high-quality data in near real-time.
Collapse
Affiliation(s)
| | | | - A Basile
- Merck & Co., Inc., Kenilworth, NJ, USA
| | | | | | | | | | | | | | | | | | | | | | | | - D Klamer
- Anavex Life Sciences Corp., NY, USA
| | | | | | | | - T Piser
- Onsero Therapeutics, MA, USA
| | | | | | | | | | | | | | | | | | - D Mathalon
- University of California, San Francisco, CA, USA
| | - W Z Potter
- Independent Consultant, Philadelphia, PA, USA
| | | | - L Ereshefsky
- CenExel Research, USA; University of Texas Health Science Center at San Antonio, TX, USA
| |
Collapse
|
6
|
Su C, Bai HX, Christensen S. Relative survival analysis in patients with stage I-II Merkel cell carcinoma treated with Mohs micrographic surgery or wide local excision. J Am Acad Dermatol 2023; 88:e131-e132. [PMID: 29787844 DOI: 10.1016/j.jaad.2018.04.057] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2018] [Revised: 04/09/2018] [Accepted: 04/12/2018] [Indexed: 11/19/2022]
Affiliation(s)
- Chang Su
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
| | - Harrison X Bai
- Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
| | - Sean Christensen
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
| |
Collapse
|
7
|
Asper J, Ramirez C, Ramos A, Christensen S, Nordwick W, Sorensen S, Newman N, Bonnen M. Implementation of a Dedicated Concurrent Chemotherapy and Radiation (C-XRT) Coordination Process can Result in Improved C-XRT Synchronization. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Asper J, Fakhreddine M, Ramirez C, Christensen S, Asper J, Rasmussen K, Corwin T, Newman N, Nordwick W, Bonnen M. Implementation of a Dedicated HDR Peer Review Program can Result in Improved Total Treatment Times for Gynecological Patients. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
9
|
Rasalingam Moerk S, Kristensen LQ, Osterlund LG, Christensen S, Tang M, Terkelsen CJ, Eiskjaer H. Long-term neurological intact survival and quality of life after refractory out-of-hospital cardiac arrest treated with rescue mechanical circulatory support. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Mechanical circulatory support (MCS) with either veno-arterial extracorporeal membrane oxygenation (V-A ECMO) or Impella has emerged as a rescue therapy for refractory out-of-hospital cardiac arrest (OHCA). However, only short-term outcome is specified and most studies do not report follow-up beyond six months. Long-term survival and quality of life in this high-risk population remains unknown.
Purpose
To determine long-term neurological intact survival and quality of life in patients with refractory OHCA treated with MCS.
Methods
This was an observational, single-centre study of OHCA-patients from January 2015 to December 2019. Patients treated with MCS for OHCA were compared with patients receiving conventional cardiopulmonary resuscitation (CPR). A follow-up of long-term survivors in the MCS group was conducted (>1 year after arrest). This included health related quality of life questionaries (Short Form-36 [SF-36]) and assessment of neurological function with Cerebral Performance Category (CPC). Good neurological outcome was defined as CPC 1 and CPC 2.
Results
A total of 1015 with OHCA were included; 101 received MCS for refractory cardiac arrest. Among these V-A ECMO was deployed in 97 patients and Impella in 4 patients. The MCS group had significantly longer low-flow times compared to the conventional group (105 [IQR, 94–123] minutes versus 18 [IQR 10–39] minutes) and were more metabolically deranged upon arrival at hospital (Table 1). In patients receiving MCS, the hospital discharge rate was 27% and good neurological outcome was seen in 93% among patients discharged. At follow-up, 15 out of 21 long-term survivors participated. Median follow-up time was 4.8±1.6 (range 2.8–6.1 years). Mean age at follow-up was 61±7.3 years, 11 (73%) were men. Neurological outcome with CPC 1 was found in 12 patients (80%), with CPC 2 in 2 patients (13%), and with CPC 3 in 1 patient (7%). Two had improved neurological status from CPC 2 to CPC 1 since discharge. Mean scores of the SF-36 revealed an overall high level of psychical and mental health in long-term survivors (Figure 1).
Conclusion
Long-term survival with good neurological outcome was high in patients with refractory OHCA treated with MCS despite prolonged resuscitation and severe metabolic derangement. These patients may expect a reasonable quality of life after discharge.
Funding Acknowledgement
Type of funding sources: Public hospital(s). Main funding source(s): Department of Cardiology, Aarhus University HospitalSnedkermester Sophus Jacobsen og hustru Astrid Jacobsens Fond
Collapse
Affiliation(s)
| | - L Q Kristensen
- Aarhus University, Department of Public Health , Aarhus , Denmark
| | - L G Osterlund
- Aarhus University Hospital, Department of Physiotherapy and Occupational Therapy (DEFACTUM) , Aarhus , Denmark
| | - S Christensen
- Aarhus University Hospital, Department of Anaesthesiology and Intensive Care , Aarhus , Denmark
| | - M Tang
- Aarhus University Hospital, Department of Thoracic and Vascular Surgery , Aarhus , Denmark
| | - C J Terkelsen
- Aarhus University Hospital, Department of Cardiology , Aarhus , Denmark
| | - H Eiskjaer
- Aarhus University Hospital, Department of Cardiology , Aarhus , Denmark
| |
Collapse
|
10
|
Gregers E, Moerk SR, Linde L, Andreasen JB, Smerup M, Kjaergaard J, Moeller-Soerensen PH, Holmvang L, Christensen S, Terkelsen CJ, Moeller JE, Lassen JF, Rieber LP, Laugesen H, Soeholm H. Extracorporeal cardiopulmonary resuscitation: a national study on the association between survival and biomarkers of hypoperfusion, inflammation, and organ failure. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
In refractory out-of-hospital cardiac arrest (OHCA) with prolonged whole-body ischemia, global tissue injury proceeds even after establishment of circulation with extracorporeal cardiopulmonary resuscitation (ECPR).
Purpose
We aimed to investigate the role of biomarkers reflecting hypoperfusion, inflammation, and organ injury in prognostication of patients with refractory OHCA managed with ECPR.
Methods
This nationwide retrospective study included 226 adults with refractory OHCA managed with ECPR in Denmark (2011–2020). Biomarkers at admission and consecutively two days after ECPR initiation were retrieved. Odds ratio (OR) of 90-day survival were assessed by logistic regression analyses. Cut-off values were calculated from area under the curve (AUC) via the Youden index.
Results
Fifty-six patients (25%) survived to hospital discharge, all were still alive after 90-days and 91% had a favorable neurological status at discharge. Factors independently associated with 90-day survival were: male sex, shockable presenting rhythm, low flow time, platelets, pH, lactate, C-reactive protein, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and creatine kinase MB (CK-MB) level. Comparing the ability of standard predictive variables (age, sex, shockable presenting rhythm, witnessed arrest, and low flow time) and selected biomarkers (from multivariate analyses) in predicting 90-day survival, biomarkers day 2 after OHCA were significantly better than standard variables (AUC 0.79 vs. 0.56, p=0.01).
Conclusion
Biomarkers of hypoperfusion (low lactate and high pH), inflammation (high platelets and CRP), and organ failure (low LDH, ALP, and CK-MB) were independently associated with 90-day survival. Biomarkers on day 2 after OHCA (d-dimer, ALP, and CK-MB) were more predictive of 90-day survival than standard predictive variables.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Odense University Hospital's and Rigshospitalet's Common Research Foundation
Collapse
Affiliation(s)
- E Gregers
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - S R Moerk
- Aarhus University Hospital , Aarhus , Denmark
| | - L Linde
- Odense University Hospital , Odense , Denmark
| | | | - M Smerup
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - J Kjaergaard
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | | | - L Holmvang
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | | | | | - J E Moeller
- Odense University Hospital , Odense , Denmark
| | - J F Lassen
- Odense University Hospital , Odense , Denmark
| | - L P Rieber
- Odense University Hospital , Odense , Denmark
| | - H Laugesen
- Aalborg University Hospital , Aalborg , Denmark
| | - H Soeholm
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| |
Collapse
|
11
|
Fonseca De Freitas D, Agbedjro D, Kadra-Scalzo G, Francis E, Ridler I, Pritchard M, Shetty H, Segev A, Casetta C, Smart S, Morris A, Downs J, Christensen S, Bak N, Kinon B, Stahl D, Hayes R, Maccabe J. Correlates of late-onset antipsychotic treatment resistance. Eur Psychiatry 2022. [PMCID: PMC9567017 DOI: 10.1192/j.eurpsy.2022.2018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction There is emerging evidence of heterogeneity within treatment-resistance schizophrenia (TRS), with some people not responding to antipsychotic treatment from illness onset and a smaller group becoming treatment-resistant after an initial response period. It has been suggested that these groups have different aetiologies. Few studies have investigated socio-demographic and clinical differences between early and late onset of TRS. Objectives This study aims to investigate socio-demographic and clinical correlates of late-onset of TRS. Methods Using data from the electronic health records of the South London and Maudsley, we identified a cohort of people with TRS. Regression analyses were conducted to identify correlates of the length of treatment to TRS. Analysed predictors include gender, age, ethnicity, positive symptoms severity, problems with activities of daily living, psychiatric comorbidities, involuntary hospitalisation and treatment with long-acting injectable antipsychotics. Results We observed a continuum of the length of treatment until TRS presentation. Having severe hallucinations and delusions at treatment start was associated shorter duration of treatment until the presentation of TRS. Conclusions Our findings do not support a clear cut categorisation between early and late TRS, based on length of treatment until treatment resistance onset. More severe positive symptoms predict earlier onset of treatment resistance. Disclosure DFdF, GKS, EF and IR have received research funding from Janssen and H. Lundbeck A/S. RDH and HS have received research funding from Roche, Pfizer, Janssen and Lundbeck. SES is employed on a grant held by Cardiff University from Takeda Pharmaceutical Comp
Collapse
|
12
|
Bundgaard JS, Mogensen UM, Christensen S, Ploug U, Rørth R, Ibsen R, Kjellberg J, Køber L. Healthcare cost variation in patients with heart failure: a nationwide study. Public Health 2022; 207:88-93. [PMID: 35594807 DOI: 10.1016/j.puhe.2022.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 01/28/2022] [Accepted: 03/29/2022] [Indexed: 10/18/2022]
Abstract
OBJECTIVE Heart failure (HF) imposes a major economic burden; however, the individual management for patients varies, potentially leading to large cost heterogeneity. The aim of this study was to investigate the spectrum of health cost by patients with HF and factors associated with high direct health cost. STUDY DESIGN This was a nationwide, retrospective longitudinal study. METHODS Using Danish nationwide registries from 2012 to 2015, we identified all patients aged >18 years with a first-time diagnosis of HF. Total health costs were investigated using two perspectives-at index and during 3 years of follow-up. Patients were investigated by decile cost groups. A multivariable logistic regression was used to identify variables associated with being in the highest cost decile compared with the rest (90%). RESULTS A total of 11,170 patients with HF were included, and those in the highest cost decile (n = 1117, 10%) were younger (69 vs. 75 years), fewer were females (34% vs. 43%), and more were inpatients (83% vs. 70%) compared with the rest of the patients with HF (n = 10,053, 90%). Patients in the highest cost decile (10%) incurred a 30 times higher cost with a mean total health cost in index year of €86,607 compared with €2893 for patients in lowest cost decile (10%). The results were similar for 3 years aggregated (€139,473 vs. €4086), corresponding to a 34 times higher cost. CONCLUSION In patients with HF, a large total health cost heterogeneity exists with younger age, inpatient admittance, male sex, and comorbidities being associated with a higher likelihood of belonging to the highest cost group.
Collapse
Affiliation(s)
- J Skov Bundgaard
- Department of Cardiology, Rigshospitalet, University Hospital, Copenhagen, Denmark.
| | - U M Mogensen
- Department of Cardiology, Rigshospitalet, University Hospital, Copenhagen, Denmark
| | | | | | - R Rørth
- Department of Cardiology, Rigshospitalet, University Hospital, Copenhagen, Denmark
| | | | - J Kjellberg
- Danish Institute for Health Services Research, Copenhagen, Denmark
| | - L Køber
- Department of Cardiology, Rigshospitalet, University Hospital, Copenhagen, Denmark
| |
Collapse
|
13
|
Christensen S, Benefield RJ. 621. Identifying Quality-Improvement Interventions to Improve Inpatient Intravenous Vancomycin Safety at an Academic Medical Center. Open Forum Infect Dis 2021. [PMCID: PMC8644053 DOI: 10.1093/ofid/ofab466.819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background The reported incidence of intravenous (IV) vancomycin-associated acute kidney injury (AKI) is highly variable. The primary purpose of this study was to determine the baseline rate of IV vancomycin-associated AKI at the University of Utah Hospital (UUH) and Huntsman Cancer Institute (HCI) with the goal of identifying areas of focus for future quality improvement (QI) initiatives. Methods This was a retrospective descriptive study of patients ≥ 18 years old, hospitalized at UUH or HCI, who received at least daily scheduled doses of IV vancomycin for ≥ 72 hours between November 1, 2018 and October 31, 2019. AKI was defined using the serum creatinine (SCr) aspect of the AKIN criteria. Variables assessed for association with AKI included demographic characteristics, hospital and unit where vancomycin was initiated, duration of therapy, administration method, and concomitant nephrotoxic medications. Multivariable logistic regression was used to identify variables independently associated with AKI as potential QI interventions. Results One thousand eighty-six patients were included. Baseline patient characteristics are listed in Table 1. Throughout our system, 19.7% of patients experienced an AKI while receiving vancomycin. Univariate comparisons are listed in Table 1. Variables independently associated with AKI on multivariable analysis included total body weight (HR 1.02, 95% CI [1.01-1.03]), concomitant administration of calcineurin inhibitors or vasopressors (HR 1.97, 95% CI [1.18-3.29] and HR 1.68, 85% CI [1.07-2.64] respectively), duration of vancomycin therapy (HR, 1.04, 95% CI [1.02-1.06]), and administration in specific units (see Table 1). Administration of vancomycin by continuous infusion showed a protective effect (HR 0.13, 95% CI [0.02-1.12]) as did baseline SCr and total daily dose of vancomycin (HR 0.76, 95% CI [0.61-0.94] and HR 0.63, 95% CI [0.51-0.78] respectively); the latter two are likely a reflection of the study design. The median hospital length of stay in days was longer in individuals experiencing an AKI (19 vs 10, p < 0.0001). Table 1. Univariate and Multivariate Associations with Vancomycin-Associated Acute Kidney Injury ![]()
aFor continuous variables, the HR reported is for each unit increase Table 1. (Continued) Univariate and Multivariate Associations with Vancomycin-Associated Acute Kidney Injury ![]()
aFor continuous variables, the HR reported is for each unit increase Conclusion Several variables associated with vancomycin-associated AKI within our health system were identified. Future QI interventions to improve vancomycin safety will be pursued. Disclosures Russell J. Benefield, PharmD, Paratek Pharmaceuticals (Grant/Research Support)
Collapse
|
14
|
Moerk SR, Stengaard C, Linde L, Moller JE, Andreasen JB, Laugesen H, Thomassen SA, Freeman PM, Christensen S, Tang M, Gregers E, Kjaergaard J, Hassager C, Eiskjaer H, Terkelsen CJ. Mechanical circulatory support for refractory out-of-hospital cardiac arrest: a nationwide multicentre study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Extracorporeal cardiopulmonary resuscitation (ECPR) has shown potential as a salvage therapy for patients with refractory out-of-hospital cardiac arrest (OHCA). Despite growing interest in and a growing body of literature on ECPR for refractory OHCA, robust evidence on patient eligibility is still lacking.
Purpose
To describe the survival, neurological outcome, and adherence to the national consensus with respect to use of ECPR for OHCA, and to identify factors associated with outcome.
Methods
Retrospective, observational cohort study of patients who underwent ECPR for OHCA at four cardiac arrest centres. Binary logistic regression and Kaplan-Meier survival curves were performed to assess association with 30-day mortality.
Results
A total of 259 patients receiving ECPR for OHCA between July 2011 and December 2020 were included in the study. Thirty-day survival was 26% and a good neurological outcome Cerebral Performance Category (CPC) 1–2 was observed in 94% of patients at discharge. Strict adherence to the national consensus showed a 30-day survival rate of 30%. Adding one or more of the following criteria to the national consensus: signs of life during cardiopulmonary resuscitation (CPR), pre-hospital low-flow <100 minutes, pH >6.8 and lactate <15 mmol/L increased the survival rate to 48%, but would exclude 58% of the survivors from the current cohort. Logistic regression identified initial presenting rhythm with asystole (RR 1.36, 95% CI 1.18–1.57), pulseless electrical activity (PEA) (RR 1.20, 95% CI 1.03–1.41), initial pH <6.8 (RR 1.28, 95% CI 1.12–1.46) and lactate levels >15 mmol/L (RR 1.16, 95% CI 1.16–1.53) as factors associated with increased risk of 30-day mortality. Patients presenting signs of life during CPR had threefold higher survival rate than patients without signs of life (45% versus 13%, p<0.001)
Conclusion
A high survival rate with a good neurological outcome was observed in this population of patients treated with ECPR for OHCA. Signs of life during CPR may aid the decision-making in the selection of appropriate candidates. Stringent patient selection for ECPR may produce higher survival rates but potentially withholds life-saving treatment in a significant proportion of survivors, why optimization of the selection criteria is still necessary.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): This work was supported by the Danish Heart Foundation [20-R142-A9498-22178]; and Health Research Foundation of Central Denmark Region [R64-A3178-B1349] Survival and adherence to consensusSigns of life during CPR
Collapse
Affiliation(s)
- S R Moerk
- Aarhus University Hospital, Department of Cardiology, Aarhus, Denmark
| | - C Stengaard
- Aarhus University Hospital, Department of Cardiology, Aarhus, Denmark
| | - L Linde
- Odense University Hospital, Department of Cardiology, Odense, Denmark
| | - J E Moller
- Odense University Hospital, Department of Cardiology, Odense, Denmark
| | - J B Andreasen
- Aalborg University Hospital, Department of Anaestesiology and Intensive Care, Aalborg, Denmark
| | - H Laugesen
- Aalborg University Hospital, Department of Anaestesiology and Intensive Care, Aalborg, Denmark
| | - S A Thomassen
- Aalborg University Hospital, Department of Anaestesiology and Intensive Care, Aalborg, Denmark
| | - P M Freeman
- Aalborg University Hospital, Department of Cardiology, Aalborg, Denmark
| | - S Christensen
- Aarhus University Hospital, Department of Anaesthesiology and Intensive Care, Aarhus, Denmark
| | - M Tang
- Aarhus University Hospital, Department of Thoracic and Vascular Surgery, Aarhus, Denmark
| | - E Gregers
- Copenhagen University Hospital, Department of Cardiology, Copenhagen, Denmark
| | - J Kjaergaard
- Copenhagen University Hospital, Department of Cardiology, Copenhagen, Denmark
| | - C Hassager
- Copenhagen University Hospital, Department of Cardiology, Copenhagen, Denmark
| | - H Eiskjaer
- Aarhus University Hospital, Department of Cardiology, Aarhus, Denmark
| | - C J Terkelsen
- Aarhus University Hospital, Department of Cardiology, Aarhus, Denmark
| |
Collapse
|
15
|
Paguigan ND, Yan Y, Karthikeyan M, Chase K, Carter J, Leavitt LS, Lim AL, Lin Z, Memon T, Christensen S, Bentzen BH, Schmitt N, Reilly CA, Teichert RW, Raghuraman S, Olivera BM, Schmidt EW. The Tunicate Metabolite 2-(3,5-Diiodo-4-methoxyphenyl)ethan-1-amine Targets Ion Channels of Vertebrate Sensory Neurons. ACS Chem Biol 2021; 16:1654-1662. [PMID: 34423964 DOI: 10.1021/acschembio.1c00328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Marine tunicates produce defensive amino-acid-derived metabolites, including 2-(3,5-diiodo-4-methoxyphenyl)ethan-1-amine (DIMTA), but their mechanisms of action are rarely known. Using an assay-guided approach, we found that out of the many different sensory cells in the mouse dorsal root ganglion (DRG), DIMTA selectively affected low-threshold cold thermosensors. Whole-cell electrophysiology experiments using DRG cells, channels expressed in Xenopus oocytes, and human cell lines revealed that DIMTA blocks several potassium channels, reducing the magnitude of the afterhyperpolarization and increasing the baseline intracellular calcium concentration [Ca2+]i of low-threshold cold thermosensors. When injected into mice, DIMTA increased the threshold of cold sensation by >3 °C. DIMTA may thus serve as a lead in the further design of compounds that inhibit problems in the cold-sensory system, such as cold allodynia and other neuropathic pain conditions.
Collapse
Affiliation(s)
- Noemi D. Paguigan
- Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 81112, United States
| | - Yannan Yan
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark
| | - Manju Karthikeyan
- Department of Biology, University of Utah, Salt Lake City, Utah 81112, United States
| | - Kevin Chase
- Department of Biology, University of Utah, Salt Lake City, Utah 81112, United States
| | - Jackson Carter
- Department of Biology, University of Utah, Salt Lake City, Utah 81112, United States
| | - Lee S. Leavitt
- Department of Biology, University of Utah, Salt Lake City, Utah 81112, United States
| | - Albebson L. Lim
- Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 81112, United States
| | - Zhenjian Lin
- Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 81112, United States
| | - Tosifa Memon
- Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 81112, United States
| | - Sean Christensen
- Department of Biology, University of Utah, Salt Lake City, Utah 81112, United States
| | - Bo H. Bentzen
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark
| | - Nicole Schmitt
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark
| | - Christopher A. Reilly
- Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 81112, United States
| | - Russell W. Teichert
- Department of Biology, University of Utah, Salt Lake City, Utah 81112, United States
| | | | - Baldomero M. Olivera
- Department of Biology, University of Utah, Salt Lake City, Utah 81112, United States
| | - Eric W. Schmidt
- Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 81112, United States
| |
Collapse
|
16
|
Gajewiak J, Christensen S, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera B, McIntosh JM. Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism. J Med Chem 2021; 64:9271-9278. [PMID: 34142837 PMCID: PMC8360267 DOI: 10.1021/acs.jmedchem.1c00512] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Venom-derived compounds are of broad interest in neuropharmacology and drug development. α-Conotoxins are small disulfide-containing peptides from Conus snails that target nicotinic acetylcholine receptors (nAChRs) and are in clinical development for non-opioid-based treatment of intractable pain. Although refined by evolution for interaction with target prey receptors, enhancements of pharmacological properties are needed for use in mammalian systems. Therefore, we synthesized analogues of α-conotoxin RgIA using a combination of selective penicillamine substitutions together with natural and non-natural amino acid replacements. This approach resulted in a peptide with 9000-fold increased potency on the human α9α10 nAChR and improved resistance to disulfide shuffling compared to the native peptide. The lead analogue, RgIA-5474, potently blocked α9α10 nAChRs, but not opioid- or other pain-related targets. In addition, RgIA-5474 effectively reversed chemotherapy-induced neuropathic pain.
Collapse
Affiliation(s)
- Joanna Gajewiak
- School of Biological Sciences, University of Utah, 257 South 1400 East, Salt Lake City, UT 84112-0840
| | - Sean Christensen
- School of Biological Sciences, University of Utah, 257 South 1400 East, Salt Lake City, UT 84112-0840
| | - Cheryl Dowell
- School of Biological Sciences, University of Utah, 257 South 1400 East, Salt Lake City, UT 84112-0840
| | - Fuaad Hararah
- School of Biological Sciences, University of Utah, 257 South 1400 East, Salt Lake City, UT 84112-0840
| | - Fernando Fisher
- School of Biological Sciences, University of Utah, 257 South 1400 East, Salt Lake City, UT 84112-0840
| | - Peter N. Huynh
- School of Biological Sciences, University of Utah, 257 South 1400 East, Salt Lake City, UT 84112-0840
| | - Baldomero Olivera
- School of Biological Sciences, University of Utah, 257 South 1400 East, Salt Lake City, UT 84112-0840
| | - J. Michael McIntosh
- School of Biological Sciences, University of Utah, 257 South 1400 East, Salt Lake City, UT 84112-0840
- George E. Wahlen Department of Veterans Affairs Medical Center, 500 Foothill Dr, Salt Lake City, UT 84148
- Department of Psychiatry, University of Utah, 501 Chipeta Way, Salt Lake City, UT 84108
| |
Collapse
|
17
|
Argyriou A, Wadsworth MH, Lendvai A, Christensen S, Hensvold A, Gerstner C, Kravarik K, Winkler A, Malmström V, Chemin K. OP0072 SINGLE CELL SEQUENCING REVEALS CLONALLY EXPANDED CYTOTOXIC CD4+ T CELLS IN THE JOINTS OF ACPA+ RA PATIENTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:CD4+ T cells with cytotoxic functions (CD4+ CTL) have gained attention in recent years. Accumulating evidence supports their importance in defense against human viral infections such as CMV1, EBV2, dengue3, HIV4, 5 and SARS-CoV-26. Moreover, expansion of so called CD28null cytotoxic CD4+ T cells have been reported in the blood of patients with rheumatic diseases such as rheumatoid arthritis (RA)7, myositis8 and vasculitis9 as well as in cardiovascular diseases10.Objectives:Here, we aimed to investigate the presence and clonal expansion of CD4+ CTL in the peripheral blood (PB) and synovial fluid (SF) of RA patients using single cell technologies.Methods:We assessed the expression of cytotoxic effector molecules and transcription factors in CD4+ T cells in synovial fluid (n=21) and paired peripheral blood (n=16) from ACPA- and APCA+ RA patients by multi-parameter flow cytometry. We performed single cell sequencing, in combination with 5´ TCRab sequencing, on purified CD4+ T cells from the peripheral blood (PB) and synovial fluid (SF) of ACPA+ RA patients (n=7).Results:Flow cytometry experiments show that Granzyme-B+ Perforin-1+ CD4+ CTL are significantly increased in the SF of ACPA+ RA patients as compared to ACPA- RA patients (p=0.0072). The presence of CD4+ CTL could be confirmed by single cell sequencing in SF of each ACPA+ RA patient tested (n=7). Moreover, we found that the adhesion G-protein coupled receptor GPR56 is selectively expressed on the recently described peripheral helper (TPH) T-cell subset11 and associates with the expression of tissue resident memory markers LAG-3, CXCR6 and CD69. In blood, we confirmed a previous report12 showing that GPR56 delineates cytotoxic CD4+ T cells. Finally, expanded TCR clones expressing cytotoxic effector molecules were identified in synovial fluid of ACPA+ RA patients and, for some patients, in their corresponding peripheral blood.Conclusion:We identified GPR56 as a marker of TPH cells in SF of ACPA+ RA patients that associates with tissue residency receptors. The combination of single cell sequencing and multi-parameter flow cytometry highlights the importance of CD4+ CTL in ACPA+ RA and suggests a potential therapeutic target (Figure 1).References:[1]Casazza J. P. et al., J Exp Med2006,203 (13), 2865-77.[2]Landais E. et al., Blood2004,103 (4), 1408-16.[3]Kurane I. et al. J Exp Med1989,170 (3), 763-75.[4]Appay V. et al. J Immunol2002,168 (11), 5954-8.[5]Juno J. A. et al. Front Immunol2017,8, 19.[6]Meckiff B. J. et al. Cell2020,183 (5), 1340-1353 e16.[7]Schmidt D. et al. J Clin Invest1996,97 (9), 2027-37.[8]Fasth A. E. et al. J Immunol2009,183 (7), 4792-9.[9]Moosig F. et al. Clin Exp Immunol1998,114 (1), 113-8.[10]Sato K. et al. J Exp Med2006,203 (1), 239-50.[11]Rao D. A., et al. Nature2017,542 (7639), 110-114.[12]Peng Y. M. et al. J Leukoc Biol2011,90 (4), 735-40.Acknowledgements:We thank the patients who donated samples and the medical staff at the Rheumatology Clinic of Karolinska University Hospital. Julia Boström, Gloria Rostvall, and Susana Hernandez Machado are acknowledged for organizing the sampling, storage, and administration of biomaterial. This study is supported by grants from Dr. Margaretha Nilssons, the Nanna Svartz, the Ulla and Gustaf af Ugglas foundations and the Swedish association against rheumatism.Disclosure of Interests:Alexandra Argyriou: None declared, Marc H Wadsworth II Employee of: Pfizer, Inc, Cambridge, MA 02139, United States, Adrian Lendvai: None declared, Stephen Christensen Employee of: Pfizer, Inc, Cambridge, MA 02139, United States, Aase Hensvold: None declared, Christina Gerstner: None declared, Kellie Kravarik Employee of: Pfizer, Inc, Cambridge, MA 02139, United States, Aaron Winkler Employee of: Pfizer, Inc, Cambridge, MA 02139, United States, Vivianne Malmström: None declared, Karine Chemin: None declared
Collapse
|
18
|
Yu Y, Xie Y, Thamm T, Gong E, Ouyang J, Christensen S, Marks MP, Lansberg MG, Albers GW, Zaharchuk G. Tissue at Risk and Ischemic Core Estimation Using Deep Learning in Acute Stroke. AJNR Am J Neuroradiol 2021; 42:1030-1037. [PMID: 33766823 DOI: 10.3174/ajnr.a7081] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Accepted: 12/28/2020] [Indexed: 01/21/2023]
Abstract
BACKGROUND AND PURPOSE In acute stroke patients with large vessel occlusions, it would be helpful to be able to predict the difference in the size and location of the final infarct based on the outcome of reperfusion therapy. Our aim was to demonstrate the value of deep learning-based tissue at risk and ischemic core estimation. We trained deep learning models using a baseline MR image in 3 multicenter trials. MATERIALS AND METHODS Patients with acute ischemic stroke from 3 multicenter trials were identified and grouped into minimal (≤20%), partial (20%-80%), and major (≥80%) reperfusion status based on 4- to 24-hour follow-up MR imaging if available or into unknown status if not. Attention-gated convolutional neural networks were trained with admission imaging as input and the final infarct as ground truth. We explored 3 approaches: 1) separate: train 2 independent models with patients with minimal and major reperfusion; 2) pretraining: develop a single model using patients with partial and unknown reperfusion, then fine-tune it to create 2 separate models for minimal and major reperfusion; and 3) thresholding: use the current clinical method relying on apparent diffusion coefficient and time-to-maximum of the residue function maps. Models were evaluated using area under the curve, the Dice score coefficient, and lesion volume difference. RESULTS Two hundred thirty-seven patients were included (minimal, major, partial, and unknown reperfusion: n = 52, 80, 57, and 48, respectively). The pretraining approach achieved the highest median Dice score coefficient (tissue at risk = 0.60, interquartile range, 0.43-0.70; core = 0.57, interquartile range, 0.30-0.69). This was higher than the separate approach (tissue at risk = 0.55; interquartile range, 0.41-0.69; P = .01; core = 0.49; interquartile range, 0.35-0.66; P = .04) or thresholding (tissue at risk = 0.56; interquartile range, 0.42-0.65; P = .008; core = 0.46; interquartile range, 0.16-0.54; P < .001). CONCLUSIONS Deep learning models with fine-tuning lead to better performance for predicting tissue at risk and ischemic core, outperforming conventional thresholding methods.
Collapse
Affiliation(s)
- Y Yu
- From the Radiology Department (Y.Y., Y.X., T.T., M.P.M., G.Z.), Stanford University, California
| | - Y Xie
- From the Radiology Department (Y.Y., Y.X., T.T., M.P.M., G.Z.), Stanford University, California
| | - T Thamm
- From the Radiology Department (Y.Y., Y.X., T.T., M.P.M., G.Z.), Stanford University, California
| | - E Gong
- Electrical Engineering Department (E.G., J.O.), Stanford University, California
| | - J Ouyang
- Electrical Engineering Department (E.G., J.O.), Stanford University, California
| | - S Christensen
- Neurology Department (S.C., M.G.L., G.W.A.), Stanford University, California
| | - M P Marks
- From the Radiology Department (Y.Y., Y.X., T.T., M.P.M., G.Z.), Stanford University, California
| | - M G Lansberg
- Neurology Department (S.C., M.G.L., G.W.A.), Stanford University, California
| | - G W Albers
- Neurology Department (S.C., M.G.L., G.W.A.), Stanford University, California
| | - G Zaharchuk
- From the Radiology Department (Y.Y., Y.X., T.T., M.P.M., G.Z.), Stanford University, California
| |
Collapse
|
19
|
Stergiou N, Wünsche E, Mes I, Schreurs M, Verlaan M, Kooijman E, Windhorst A, Dongen G, Helboe L, Vergo S, Christensen S, Asuni A, Jensen A, Bang-Andersen B, Vugts D, Beaino W. Corrigendum to “SSP-27: 89Zr-immuno-PET of a novel bispecific amyloid β monoclonal antibody reveals improved and high specific brain uptake” [Nucl Med Biol (2020) Volumes 96–97, Supplement. S30-S31]. Nucl Med Biol 2021. [DOI: 10.1016/j.nucmedbio.2021.05.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
20
|
Hone AJ, Kaas Q, Kearns I, Hararah F, Gajewiak J, Christensen S, Craik DJ, McIntosh JM. Computational and Functional Mapping of Human and Rat α6β4 Nicotinic Acetylcholine Receptors Reveals Species-Specific Ligand-Binding Motifs. J Med Chem 2021; 64:1685-1700. [PMID: 33523678 PMCID: PMC8382285 DOI: 10.1021/acs.jmedchem.0c01973] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Nicotinic acetylcholine receptors (nAChRs) are pharmacological targets for the treatment of neuropathic pain, and the α6β4 subtype has been identified as particularly promising. Rat α6β4 nAChRs are less sensitive to some ligands than the human homologue potentially complicating the use of rodent α6β4 receptors for screening therapeutic compounds. We used molecular dynamics simulations coupled with functional assays to study the interaction between α-conotoxin PeIA and α6β4 nAChRs and to identify key ligand-receptor interactions that contribute to species differences in α-conotoxin potency. Our results show that human and rat α6β4 nAChRs have distinct ligand-binding motifs and show markedly different sensitivities to α-conotoxins. These studies facilitated the creation of PeIA-5667, a peptide that shows 270-fold higher potency for rat α6β4 nAChRs over native PeIA and similar potency for the human homologue. Our results may inform the design of therapeutic ligands that target α6β4 nAChRs for the treatment of neuropathic pain.
Collapse
Affiliation(s)
- Arik J Hone
- MIRECC, George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah 84148 United States
| | - Quentin Kaas
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, Queensland 4072 Australia
| | | | | | | | | | - David J Craik
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, Queensland 4072 Australia
| | - J Michael McIntosh
- George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah 84148 United States
| |
Collapse
|
21
|
Funke B, Spinner CD, Wolf E, Heiken H, Christensen S, Stellbrink HJ, Witte V. High prevalence of comorbidities and use of concomitant medication in treated people living with HIV in Germany - results of the BESIDE study. Int J STD AIDS 2020; 32:152-161. [PMID: 33323070 DOI: 10.1177/0956462420942020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Due to demographic changes in people living with HIV (PLHIV), physicians are challenged with age-related comorbidities and their management. In the absence of comprehensive data collection, the burden of comorbidities and co-medication in addition to antiretroviral therapy (ART) remains unclear for the German real-world setting. BESIDE was an observational, cross-sectional study evaluating the prevalence of comorbidities and use of co-medication in treated PLHIV. Regional distribution of study centers (n = 20), consecutive patient recruitment, and age-stratified sampling in alignment with national epidemiologic data aimed to ensure a representative sample (n = 453). The overall prevalence of comorbidities was 91.2%; 31.6% of patients had ≥4 comorbidities. The most common diagnoses were vitamin D deficiency (29.1%), depressive episode (27.8%), arterial hypertension (16.3%), and hypercholesterolemia (10.8%). 83.7% of patients were on co-medication; 21.2% taking ≥4 medications. The most common medications or supplements were vitamins (31.6%), anti-inflammatory agents (16.1%), renin-angiotensin system agents (12.1%), acid suppressants (11.7%), lipid modifying agents (10.8%); 1.3% of patients were on co-medication that should not be co-administered with ART, 41.5% on co-medication with potential for drug-drug interactions. The prevalence of comorbidities and use of co-medication among treated PLHIV in Germany is consistently high and increases across age groups, illustrating the complexity of HIV care involving appropriate ART selection.
Collapse
Affiliation(s)
- B Funke
- MSD Sharp & Dohme GmbH, Medical Affairs, Haar, Germany
| | - C D Spinner
- Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Munich, Germany
| | - E Wolf
- MUC Research, Munich, Germany.,MVZ Karlsplatz, HIV Research and Clinical Care Centre, Munich, Germany
| | - H Heiken
- Praxis Georgstrasse, Hanover, Germany
| | - S Christensen
- Center for Interdisciplinary Medicine (CIM) Infectious Diseases, Muenster, Germany
| | | | - V Witte
- MSD Sharp & Dohme GmbH, Medical Affairs, Haar, Germany
| |
Collapse
|
22
|
Perni S, Bitterman D, Ryan J, Silver J, Mitchell E, Christensen S, Bloom M, Hochberg E, Ryan D, Haas-Kogan D, Tarbell N, Parikh A, Wo J. Gender Disparities in Philanthropic Fundraising by Academic Oncologists. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Obeid JS, Dahne J, Christensen S, Howard S, Crawford T, Frey LJ, Stecker T, Bunnell BE. Identifying and Predicting Intentional Self-Harm in Electronic Health Record Clinical Notes: Deep Learning Approach. JMIR Med Inform 2020; 8:e17784. [PMID: 32729840 PMCID: PMC7426805 DOI: 10.2196/17784] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 04/25/2020] [Accepted: 05/21/2020] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Suicide is an important public health concern in the United States and around the world. There has been significant work examining machine learning approaches to identify and predict intentional self-harm and suicide using existing data sets. With recent advances in computing, deep learning applications in health care are gaining momentum. OBJECTIVE This study aimed to leverage the information in clinical notes using deep neural networks (DNNs) to (1) improve the identification of patients treated for intentional self-harm and (2) predict future self-harm events. METHODS We extracted clinical text notes from electronic health records (EHRs) of 835 patients with International Classification of Diseases (ICD) codes for intentional self-harm and 1670 matched controls who never had any intentional self-harm ICD codes. The data were divided into training and holdout test sets. We tested a number of algorithms on clinical notes associated with the intentional self-harm codes using the training set, including several traditional bag-of-words-based models and 2 DNN models: a convolutional neural network (CNN) and a long short-term memory model. We also evaluated the predictive performance of the DNNs on a subset of patients who had clinical notes 1 to 6 months before the first intentional self-harm event. Finally, we evaluated the impact of a pretrained model using Word2vec (W2V) on performance. RESULTS The area under the receiver operating characteristic curve (AUC) for the CNN on the phenotyping task, that is, the detection of intentional self-harm in clinical notes concurrent with the events was 0.999, with an F1 score of 0.985. In the predictive task, the CNN achieved the highest performance with an AUC of 0.882 and an F1 score of 0.769. Although pretraining with W2V shortened the DNN training time, it did not improve performance. CONCLUSIONS The strong performance on the first task, namely, phenotyping based on clinical notes, suggests that such models could be used effectively for surveillance of intentional self-harm in clinical text in an EHR. The modest performance on the predictive task notwithstanding, the results using DNN models on clinical text alone are competitive with other reports in the literature using risk factors from structured EHR data.
Collapse
Affiliation(s)
- Jihad S Obeid
- Medical University of South Carolina, Charleston, SC, United States
| | - Jennifer Dahne
- Medical University of South Carolina, Charleston, SC, United States
| | - Sean Christensen
- Medical University of South Carolina, Charleston, SC, United States
| | - Samuel Howard
- Medical University of South Carolina, Charleston, SC, United States
| | - Tami Crawford
- Medical University of South Carolina, Charleston, SC, United States
| | - Lewis J Frey
- Medical University of South Carolina, Charleston, SC, United States
| | - Tracy Stecker
- Medical University of South Carolina, Charleston, SC, United States
| | | |
Collapse
|
24
|
Byyny RL, Martinez D, Cleary L, Ballard B, Barth BE, Christensen S, Eidson-Ton W, Estevez-Ordonez D, Fuhrer J, Kinzie JM, Lee AL, Lynch C, Pfeil S, Schoenbaum E. Alpha Omega Alpha Honor Medical Society: A Commitment to Inclusion, Diversity, Equity, and Service in the Profession of Medicine. Acad Med 2020; 95:670-673. [PMID: 31764080 DOI: 10.1097/acm.0000000000003088] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
With a motto of "Be Worthy to Serve the Suffering," Alpha Omega Alpha Honor Medical Society (AΩA) supports the importance, inclusion, and development of a culturally and ethnically diverse medical profession with equitable access for all. The underrepresentation of minorities in medical schools and medicine continues to be a challenge for the medical profession, medical education, and AΩA. AΩA has worked, and continues to work, to ensure the development of diverse leaders, fostering within them the objectivity and equity to be inclusive servant leaders who understand and embrace diversity in all its forms.Inclusion of talented individuals from different backgrounds benefits patient care, population health, education, and scientific discovery. AΩA values an inclusive, diverse, fair, and equitable work and learning environment for all and supports the medical profession in its work to achieve a welcoming, inclusive environment in teaching, learning, caring for patients, and collaboration.The diversity of medical schools is changing and will continue to change. AΩA is committed to continuing to work with its members, medical school deans, and AΩA chapters to assure that AΩA elections are unbiased and based on the values of AΩA and the profession of medicine in service to patients and the profession.Progress toward diversity, inclusion, and equity is more than simply checking off a box or responding to criticism-it is about being and developing diverse excellent physicians. AΩA and all those in the medical profession must continue to guide medicine to be unbiased, open, accepting, inclusive, and culturally aware in order to "Be Worthy to Serve the Suffering."
Collapse
Affiliation(s)
- Richard L Byyny
- R.L. Byyny is executive director, Alpha Omega Alpha Honor Medical Society, Aurora, Colorado, chancellor emeritus, University of Colorado Boulder, Boulder, Colorado, and a retired internal medicine physician. D. Martinez is chief of staff, Alpha Omega Alpha Honor Medical Society, Aurora, Colorado. L. Cleary is associate dean for curriculum, senior associate dean for education, vice president for academic affairs, and AΩA chapter councilor, State University of New York, Upstate, Syracuse, New York. B. Ballard is associate dean for continuing medical education, chairman and professor of pathology, and AΩA chapter councilor, Meharry Medical College, Nashville, Tennessee; ORCID: https://orcid.org/0000-0001-7202-2506. B.E. Barth is associate professor, emergency medicine, and assistant dean for student affairs, University of Kansas Medical Center, Kansas City, Kansas; ORCID: https://orcid.org/0000-0003-3996-1346. S. Christensen is a psychiatry resident and drug abuse and research training fellow, Medical University of South Carolina, Charleston, South Carolina; ORCID: https://orcid.org/0000-0002-0702-1862. W. Eidson-Ton is professor of family medicine and obstetrics and AΩA chapter councilor, University of California, Davis, Sacramento, California. D. Estevez-Ordonez is a neurosurgery resident, University of Alabama at Birmingham, Birmingham, Alabama, and a student director, AΩA Board of Directors. J. Fuhrer is associate dean for admissions, director, HIV Treatment Center, associate professor of medicine, and AΩA chapter councilor, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York. J.M. Kinzie is associate professor of psychiatry and AΩA chapter councilor, Oregon Health & Science University, Portland, Oregon. A.L. Lee is assistant professor, Department of Family Medicine, and AΩA chapter councilor, Tufts University School of Medicine, Boston, Massachusetts; ORCID: https://orcid.org/0000-0001-7956-4746. C. Lynch is associate vice president, College of Medicine obstetrics and gynecology, associate vice president, women's health and faculty development, associate dean, faculty development, professor, obstetrics and gynecology, and AΩA chapter councilor, University of South Florida, Tampa, Florida; ORCID: https://orcid.org/0000-0002-6478-2561. S. Pfeil is medical director, Clinical Skills Education and Assessment Center, professor, Division of Gastroenterology, Hepatology and Nutrition, and AΩA chapter councilor, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, Ohio. E. Schoenbaum is professor, Department of Epidemiology & Population Health, professor, Department of Medicine, Infectious Diseases, director, Medical Student Research, Office of Medical Education, and AΩA chapter councilor, Albert Einstein College of Medicine, New York City, New York; ORCID: http://orcid.org/0000-0002-0878-284X
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Nowak SH, Armenta R, Schwartz CP, Gallo A, Abraham B, Garcia-Esparza AT, Biasin E, Prado A, Maciel A, Zhang D, Day D, Christensen S, Kroll T, Alonso-Mori R, Nordlund D, Weng TC, Sokaras D. A versatile Johansson-type tender x-ray emission spectrometer. Rev Sci Instrum 2020; 91:033101. [PMID: 32259983 DOI: 10.1063/1.5121853] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Accepted: 02/13/2020] [Indexed: 05/23/2023]
Abstract
We present a high energy resolution x-ray spectrometer for the tender x-ray regime (1.6-5.0 keV) that was designed and operated at Stanford Synchrotron Radiation Lightsource. The instrument is developed on a Rowland geometry (500 mm of radius) using cylindrically bent Johansson analyzers and a position sensitive detector. By placing the sample inside the Rowland circle, the spectrometer operates in an energy-dispersive mode with a subnatural line-width energy resolution (∼0.32 eV at 2400 eV), even when an extended incident x-ray beam is used across a wide range of diffraction angles (∼30° to 65°). The spectrometer is enclosed in a vacuum chamber, and a sample chamber with independent ambient conditions is introduced to enable a versatile and fast-access sample environment (e.g., solid/gas/liquid samples, in situ cells, and radioactive materials). The design, capabilities, and performance are presented and discussed.
Collapse
Affiliation(s)
- S H Nowak
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - R Armenta
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - C P Schwartz
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - A Gallo
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - B Abraham
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - A T Garcia-Esparza
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - E Biasin
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - A Prado
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - A Maciel
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - D Zhang
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - D Day
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - S Christensen
- National Renewable Energy Laboratory, 15013 Denver West Parkway, Golden, Colorado 80401, USA
| | - T Kroll
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - R Alonso-Mori
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - D Nordlund
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - T-C Weng
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| | - D Sokaras
- SLAC National Accelerator Laboratory, 2575 Sand Hill Rd., Menlo Park, California 94025, USA
| |
Collapse
|
26
|
Hone AJ, Rueda-Ruzafa L, Gordon TJ, Gajewiak J, Christensen S, Dyhring T, Albillos A, McIntosh JM. Expression of α3β2β4 nicotinic acetylcholine receptors by rat adrenal chromaffin cells determined using novel conopeptide antagonists. J Neurochem 2020; 154:158-176. [PMID: 31967330 DOI: 10.1111/jnc.14966] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 12/17/2019] [Accepted: 01/13/2020] [Indexed: 01/07/2023]
Abstract
Adrenal chromaffin cells release neurotransmitters in response to stress and may be involved in conditions such as post-traumatic stress and anxiety disorders. Neurotransmitter release is triggered, in part, by activation of nicotinic acetylcholine receptors (nAChRs). However, despite decades of use as a model system for studying exocytosis, the nAChR subtypes involved have not been pharmacologically identified. Quantitative real-time PCR of rat adrenal medulla revealed an abundance of mRNAs for α3, α7, β2, and β4 subunits. Whole-cell patch-clamp electrophysiology of chromaffin cells and subtype-selective ligands were used to probe for nAChRs derived from the mRNAs found in adrenal medulla. A novel conopeptide antagonist, PeIA-5469, was created that is highly selective for α3β2 over other nAChR subtypes heterologously expressed in Xenopus laevis oocytes. Experiments using PeIA-5469 and the α3β4-selective α-conotoxin TxID revealed that rat adrenal medulla contain two populations of chromaffin cells that express either α3β4 nAChRs alone or α3β4 together with the α3β2β4 subtype. Conclusions were derived from observations that acetylcholine-gated currents in some cells were sensitive to inhibition by PeIA-5469 and TxID, while in other cells, currents were sensitive only to TxID. Expression of functional α7 nAChRs was determined using three α7-selective ligands: the agonist PNU282987, the positive allosteric modulator PNU120596, and the antagonist α-conotoxin [V11L,V16D]ArIB. The results of these studies identify for the first time the expression of α3β2β4 nAChRs as well as functional α7 nAChRs by rat adrenal chromaffin cells.
Collapse
Affiliation(s)
- Arik J Hone
- George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah, USA.,School of Biological Sciences and University of Utah, Salt Lake City, Utah, USA.,Departament of Pharmacology and Therapeutics, Universidad Autónoma de Madrid, Madrid, Spain
| | - Lola Rueda-Ruzafa
- Departament of Pharmacology and Therapeutics, Universidad Autónoma de Madrid, Madrid, Spain.,Biomedical Research Center (CINBIO), University of Vigo, Vigo, Spain
| | - Thomas J Gordon
- School of Biological Sciences and University of Utah, Salt Lake City, Utah, USA
| | - Joanna Gajewiak
- School of Biological Sciences and University of Utah, Salt Lake City, Utah, USA
| | - Sean Christensen
- School of Biological Sciences and University of Utah, Salt Lake City, Utah, USA
| | | | - Almudena Albillos
- Departament of Pharmacology and Therapeutics, Universidad Autónoma de Madrid, Madrid, Spain
| | - J Michael McIntosh
- George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah, USA.,School of Biological Sciences and University of Utah, Salt Lake City, Utah, USA.,Department of Psychiatry, University of Utah, Salt Lake City, Utah, USA
| |
Collapse
|
27
|
Christensen S, Monteavaro C, Purslow PP. Single-nucleotide polymorphisms for matrix metalloprotease-1 can affect perimysial strength and intramuscular fat content but not growth rate of cattle. Anim Prod Sci 2020. [DOI: 10.1071/an18789] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Context
Single-nucleotide polymorphisms (SNPs) in the gene coding for matrix metalloprotease-1 (MMP-1) are known to affect the level of intramuscular fat found in cattle. As well as a signalling molecule affecting adipogenesis, MMP-1 is a major collagenase involved in the turnover of connective tissue.
Aims
The aim of the work was to assess whether SNPs in the gene for MMP-1 may affect the mechanical properties of intramuscular connective tissue, and therefore meat texture.
Methods
Allelic frequencies of three SNPs for MMP-1 were determined in a group of black Aberdeen Angus cattle whose growth characteristics had been traced for 450 days before slaughter. Associations between the alleles of each of the three SNPs and growth rate, killing out percentage, half-carcass weight, intramuscular fat content, cooking loss, strength of perimysium in cooked M. semitendinosus and Warner–Bratzler peak force of cooked M. longissimus dorsi were studied.
Key results
None of the SNPs studied had any effect on growth curves, and only one SNP (ss77831914) showed differences in half-carcass weight between alleles. Carcass yield and killing out percentage showed a small difference between alleles of ss7783924. No effects were found on the Warner–Bratzler peak force of M. longissimus dorsi cooked to 70°C. Two SNPs (ss77831914 and ss77831924) showed significant differences between alleles in the raw strength of perimysium in M. semitendinosus and the amount of intramuscular fat.
Conclusions
Commonly occurring SNPs of the major collagenase MMP-1 can affect the strength of intramuscular connective tissue as well as intramuscular fat content. Although these differences in connective tissue strength do not influence Warner–Bratzler measures of toughness at a cooking temperature of 70°C, they may contribute to differences in toughness in low-temperature, long-time cooking.
Implications
Because none of the SNPs had effects on the growth curves of the cattle studied, selection of animals with the relevant alleles of SNPs ss77831914 ss77831924 could be used to produce more tender meat without affecting carcass yield.
Collapse
|
28
|
Bundgaard JS, Mogensen UM, Christensen S, Ploug UM, Roerth R, Ibsen R, Kjellberg J, Koeber L. P3812The economic burden of heart failure in Denmark from 1998 to 2016. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Heart failure (HF) imposes a large burden on the individual as well as society and the aim of this study was to investigate the economic burden attributed to direct and indirect costs of patients with HF before, at, and after time of diagnosis.
Methods
Using Danish nationwide registries we identified all patients >18 years with a first-time diagnosis of HF from 1998–2016 and matched them 1:1 with a control group from the background population on age, gender, marital status, and educational level. The economic analysis of the total costs after diagnosis was based on direct costs including hospitalization, procedures, medication, and indirect costs including social welfare and lost productivity to estimate the annual cost of HF.
Results
We included a total of 176,067 HF patients with a median age of 76 years, and 55% were male. Patients with HF incurred an average of €17,039 in sum of total annual direct (€11,926) and indirect (€5,113) health-care costs peaking at year of diagnosis compared to €5,936 in the control group with the majorityattributable to inpatient admissions. The total annual net costs including social transfer after index HF were €11,957 higher in patients with HF compared to controls and the economic consequences increased markedly 2 years prior to the diagnosis of HF (Figure 1).
Conclusion
Patients with HF impose significantly higher total annual health-care costs compared to a matched control group with findings evident more than 2 years prior to HF diagnosis
Acknowledgement/Funding
Novartis
Collapse
Affiliation(s)
- J S Bundgaard
- Rigshospitalet - Copenhagen University Hospital, Cardiology, Copenhagen, Denmark
| | - U M Mogensen
- Rigshospitalet - Copenhagen University Hospital, Cardiology, Copenhagen, Denmark
| | | | | | - R Roerth
- Rigshospitalet - Copenhagen University Hospital, Cardiology, Copenhagen, Denmark
| | | | - J Kjellberg
- Danish Institute for Health Services Research, Copenhagen, Denmark
| | - L Koeber
- Rigshospitalet - Copenhagen University Hospital, Cardiology, Copenhagen, Denmark
| |
Collapse
|
29
|
Gok E, Alghanem F, Lim E, Sarver D, Eckhardt L, Christensen S, Hoenerhoff M, Mendias C, Ozer K. Single Muscle Fibre Contractility Testing in Rats to Quantify Ischaemic Muscle Damage During Reperfusion Injury. J Vasc Surg 2019. [DOI: 10.1016/j.jvs.2019.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Hone AJ, Fisher F, Christensen S, Gajewiak J, Larkin D, Whiteaker P, McIntosh JM. PeIA-5466: A Novel Peptide Antagonist Containing Non-natural Amino Acids That Selectively Targets α3β2 Nicotinic Acetylcholine Receptors. J Med Chem 2019; 62:6262-6275. [PMID: 31194549 DOI: 10.1021/acs.jmedchem.9b00566] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Pharmacologically distinguishing α3β2 nicotinic acetylcholine receptors (nAChRs) from closely related subtypes, particularly α6β2, has been challenging due to the lack of subtype-selective ligands. We created analogs of α-conotoxin (α-Ctx) PeIA to identify ligand-receptor interactions that could be exploited to selectively increase potency and selectivity for α3β2 nAChRs. A series of PeIA analogs were synthesized by replacing amino acid residues in the second disulfide loop with standard or nonstandard residues and assessing their activity on α3β2 and α6/α3β2β3 nAChRs heterologously expressed in Xenopus laevis oocytes. Asparagine11 was found to occupy a pivotal position, and when replaced with negatively charged amino acids, selectivity for α3β2 over α6/α3β2β3 nAChRs was substantially increased. Second generation peptides were then designed to further improve both potency and selectivity. One peptide, PeIA-5466, was ∼300-fold more potent on α3β2 than α6/α3β2β3 and is the most α3β2-selective antagonist heretofore reported.
Collapse
Affiliation(s)
| | | | | | | | | | | | - J Michael McIntosh
- George E. Whalen Veterans Affairs Medical Center , Salt Lake City , Utah 84148 , United States
| |
Collapse
|
31
|
Schjørring OL, Toft‐Petersen AP, Kusk KH, Mouncey P, Sørensen EE, Berezowicz P, Bestle MH, Bülow H, Bundgaard H, Christensen S, Iversen SA, Kirkeby‐Garstad I, Krarup KB, Kruse M, Laake JH, Liboriussen L, Læbel RL, Okkonen M, Poulsen LM, Russell L, Sjövall F, Sunde K, Søreide E, Waldau T, Walli AR, Perner A, Wetterslev J, Rasmussen BS. Intensive care doctors' preferences for arterial oxygen tension levels in mechanically ventilated patients. Acta Anaesthesiol Scand 2018; 62:1443-1451. [PMID: 29926908 DOI: 10.1111/aas.13171] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 05/01/2018] [Accepted: 05/04/2018] [Indexed: 12/19/2022]
Abstract
BACKGROUND Oxygen is liberally administered in intensive care units (ICUs). Nevertheless, ICU doctors' preferences for supplementing oxygen are inadequately described. The aim was to identify ICU doctors' preferences for arterial oxygenation levels in mechanically ventilated adult ICU patients. METHODS In April to August 2016, an online multiple-choice 17-part-questionnaire was distributed to 1080 ICU doctors in seven Northern European countries. Repeated reminder e-mails were sent. The study ended in October 2016. RESULTS The response rate was 63%. When evaluating oxygenation 52% of respondents rated arterial oxygen tension (PaO2 ) the most important parameter; 24% a combination of PaO2 and arterial oxygen saturation (SaO2 ); and 23% preferred SaO2 . Increasing, decreasing or not changing a default fraction of inspired oxygen of 0.50 showed preferences for a PaO2 around 8 kPa in patients with chronic obstructive pulmonary disease, a PaO2 around 10 kPa in patients with healthy lungs, acute respiratory distress syndrome or sepsis, and a PaO2 around 12 kPa in patients with cardiac or cerebral ischaemia. Eighty per cent would accept a PaO2 of 8 kPa or lower and 77% would accept a PaO2 of 12 kPa or higher in a clinical trial of oxygenation targets. CONCLUSION Intensive care unit doctors preferred PaO2 to SaO2 in monitoring oxygen treatment when peripheral oxygen saturation was not included in the question. The identification of PaO2 as the preferred target and the thorough clarification of preferences are important when ascertaining optimal oxygenation targets. In particular when designing future clinical trials of higher vs lower oxygenation targets in ICU patients.
Collapse
Affiliation(s)
- O. L. Schjørring
- Department of Anaesthesia and Intensive Care Medicine Aalborg University Hospital Aalborg Denmark
- Department of Clinical Medicine Aalborg University Aalborg Denmark
| | - A. P. Toft‐Petersen
- Department of Clinical Medicine Aalborg University Aalborg Denmark
- Intensive Care National Audit & Research Centre (ICNARC) London UK
| | - K. H. Kusk
- Clinical Nursing Research Unit Aalborg University Hospital Aalborg Denmark
| | - P. Mouncey
- Intensive Care National Audit & Research Centre (ICNARC) London UK
| | - E. E. Sørensen
- Department of Clinical Medicine Aalborg University Aalborg Denmark
- Clinical Nursing Research Unit Aalborg University Hospital Aalborg Denmark
| | - P. Berezowicz
- Department of Anaesthesia and Intensive Care Medicine Vejle Hospital Vejle Denmark
| | - M. H. Bestle
- Department of Anaesthesia and Intensive Care Medicine Nordsjaellands Hospital Hillerød Denmark
| | - H.‐H. Bülow
- Department of Anaesthesia and Intensive Care Medicine Holbæk Hospital Holbæk Denmark
| | - H. Bundgaard
- Department of Anaesthesia and Intensive Care Randers Hospital Randers Denmark
| | - S. Christensen
- Department of Anaesthesia and Intensive Care Medicine Aarhus University Hospital Skejby Denmark
| | - S. A. Iversen
- Department of Anaesthesia and Intensive Care Medicine Slagelse Hospital Slagelse Denmark
| | - I. Kirkeby‐Garstad
- Department of Anaesthesia and Intensive Care Medicine St. Olav's Hospital Trondheim Norway
- Norwegian University of Science and Technology (NTNU) Trondheim Norway
| | - K. B. Krarup
- Department of Anaesthesia and Intensive Care Odense University Hospital Odense Denmark
| | - M. Kruse
- Department of Anaesthesia and Intensive Care North Denmark Regional Hospital Hjørring Denmark
| | - J. H. Laake
- Division of Emergencies and Critical Care Rikshospitalet Oslo University Hospital Oslo Norway
| | - L. Liboriussen
- Department of Anaesthesia and Intensive Care Medicine Viborg Hospital Viborg Denmark
| | - R. L. Læbel
- Department of Anaesthesia and Intensive Care Medicine Regional Hospital West Jutland Herning Denmark
| | - M. Okkonen
- Department of Perioperative, Intensive Care and Pain Medicine Helsinki University Hospital Helsinki Finland
| | - L. M. Poulsen
- Department of Anaesthesia and Intensive Care Medicine Zealand University Hospital Køge Denmark
| | - L. Russell
- Department of Anaesthesia and Intensive Care Medicine Hvidovre Hospital Hvidovre Denmark
| | - F. Sjövall
- Department of Intensive Care and Perioperative Medicine Skåne University Hospital Malmö Sweden
- Department of Clinical Science Lund University Lund Sweden
| | - K. Sunde
- Department of Anaeshesiology Oslo University Hospital Ullevål Norway
- Institute of Clinical Medicine University of Oslo Oslo Norway
| | - E. Søreide
- Department of Anaesthesia and Intensive Care Medicine Stavanger University Hospital Stavanger Norway
| | - T. Waldau
- Department of Anaesthesia and Intensive Care Medicine Herlev Hospital Herlev Denmark
| | - A. R. Walli
- Department of Anaesthesia and Intensive Care Medicine Zealand University Hospital Roskilde Denmark
| | - A. Perner
- Department of Intensive Care Rigshospitalet Centre for Research in Intensive Care (CRIC) Copenhagen Denmark
- Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
| | - J. Wetterslev
- Copenhagen Trial Unit Rigshospitalet Centre for Clinical Intervention Research Copenhagen Denmark
| | - B. S. Rasmussen
- Department of Anaesthesia and Intensive Care Medicine Aalborg University Hospital Aalborg Denmark
- Department of Clinical Medicine Aalborg University Aalborg Denmark
| |
Collapse
|
32
|
Hone AJ, Talley TT, Bobango J, Huidobro Melo C, Hararah F, Gajewiak J, Christensen S, Harvey PJ, Craik DJ, McIntosh JM. Molecular determinants of α-conotoxin potency for inhibition of human and rat α6β4 nicotinic acetylcholine receptors. J Biol Chem 2018; 293:17838-17852. [PMID: 30249616 DOI: 10.1074/jbc.ra118.005649] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 09/20/2018] [Indexed: 12/15/2022] Open
Abstract
Nicotinic acetylcholine receptors (nAChRs) containing α6 and β4 subunits are expressed by dorsal root ganglion neurons and have been implicated in neuropathic pain. Rodent models are often used to evaluate the efficacy of analgesic compounds, but species differences may affect the activity of some nAChR ligands. A previous candidate α-conotoxin-based therapeutic yielded promising results in rodent models, but failed in human clinical trials, emphasizing the importance of understanding species differences in ligand activity. Here, we show that human and rat α6/α3β4 nAChRs expressed in Xenopus laevis oocytes exhibit differential sensitivity to α-conotoxins. Sequence homology comparisons of human and rat α6β4 nAChR subunits indicated that α6 residues forming the ligand-binding pocket are highly conserved between the two species, but several residues of β4 differed, including a Leu-Gln difference at position 119. X-ray crystallography of α-conotoxin PeIA complexed with the Aplysia californica acetylcholine-binding protein (AChBP) revealed that binding of PeIA orients Pro13 in close proximity to residue 119 of the AChBP complementary subunit. Site-directed mutagenesis studies revealed that Leu119 of human β4 contributes to higher sensitivity of human α6/α3β4 nAChRs to α-conotoxins, and structure-activity studies indicated that PeIA Pro13 is critical for high potency. Human and rat α6/α3β4 nAChRs displayed differential sensitivities to perturbations of the interaction between PeIA Pro13 and residue 119 of the β4 subunit. These results highlight the potential significance of species differences in α6β4 nAChR pharmacology that should be taken into consideration when evaluating the activity of candidate human therapeutics in rodent models.
Collapse
Affiliation(s)
| | | | - Janet Bobango
- Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59812
| | | | | | | | | | - Peta J Harvey
- Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | - David J Craik
- Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | - J Michael McIntosh
- From the Departments of Biology; Psychiatry, University of Utah, Salt Lake City, Utah 84112; George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah 84148.
| |
Collapse
|
33
|
Rasmussen BS, Christensen S, Bisgaard J, Christiansen C, Riddersholm S. Return to work after cardiac surgery. J Cardiothorac Vasc Anesth 2018. [DOI: 10.1053/j.jvca.2018.08.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
34
|
Frederiksen CA, Nielsen R, Frederiksen AS, Christensen S, Greisen J, Vase H, Logstrup BB, Mellemkjaer S, Wiggers H, Molgaard H, Terkelsen CJ, Poulsen SH, Eiskjaer H. P5689Echocardiographic predictors for successful weaning from veno-arterial extracorporeal membrane oxygenation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- C A Frederiksen
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| | - R Nielsen
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| | - A S Frederiksen
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| | - S Christensen
- Aarhus University Hospital, Department of Anesthesia and Intensive Care Medicine, Aarhus, Denmark
| | - J Greisen
- Aarhus University Hospital, Department of Anesthesia and Intensive Care Medicine, Aarhus, Denmark
| | - H Vase
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| | - B B Logstrup
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| | - S Mellemkjaer
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| | - H Wiggers
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| | - H Molgaard
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| | - C J Terkelsen
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| | - S H Poulsen
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| | - H Eiskjaer
- Aarhus University Hospital, Department of Cadiology, Aarhus, Denmark
| |
Collapse
|
35
|
Neve P, Barney JN, Buckley Y, Cousens RD, Graham S, Jordan NR, Lawton‐Rauh A, Liebman M, Mesgaran MB, Schut M, Shaw J, Storkey J, Baraibar B, Baucom RS, Chalak M, Childs DZ, Christensen S, Eizenberg H, Fernández‐Quintanilla C, French K, Harsch M, Heijting S, Harrison L, Loddo D, Macel M, Maczey N, Merotto A, Mortensen D, Necajeva J, Peltzer DA, Recasens J, Renton M, Riemens M, Sønderskov M, Williams M, Rew L. Reviewing research priorities in weed ecology, evolution and management: a horizon scan. Weed Res 2018; 58:250-258. [PMID: 30069065 PMCID: PMC6055875 DOI: 10.1111/wre.12304] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/21/2017] [Accepted: 02/05/2018] [Indexed: 05/12/2023]
Abstract
Weedy plants pose a major threat to food security, biodiversity, ecosystem services and consequently to human health and wellbeing. However, many currently used weed management approaches are increasingly unsustainable. To address this knowledge and practice gap, in June 2014, 35 weed and invasion ecologists, weed scientists, evolutionary biologists and social scientists convened a workshop to explore current and future perspectives and approaches in weed ecology and management. A horizon scanning exercise ranked a list of 124 pre-submitted questions to identify a priority list of 30 questions. These questions are discussed under seven themed headings that represent areas for renewed and emerging focus for the disciplines of weed research and practice. The themed areas considered the need for transdisciplinarity, increased adoption of integrated weed management and agroecological approaches, better understanding of weed evolution, climate change, weed invasiveness and finally, disciplinary challenges for weed science. Almost all the challenges identified rested on the need for continued efforts to diversify and integrate agroecological, socio-economic and technological approaches in weed management. These challenges are not newly conceived, though their continued prominence as research priorities highlights an ongoing intransigence that must be addressed through a more system-oriented and transdisciplinary research agenda that seeks an embedded integration of public and private research approaches. This horizon scanning exercise thus set out the building blocks needed for future weed management research and practice; however, the challenge ahead is to identify effective ways in which sufficient research and implementation efforts can be directed towards these needs.
Collapse
Affiliation(s)
- P Neve
- Rothamsted ResearchBiointeractions & Crop Protection DepartmentHarpendenHertfordshireUK
| | - J N Barney
- Department of Plant Pathology, Physiology and Weed ScienceVirginia TechBlacksburgVAUSA
| | - Y Buckley
- School of Natural Sciences, ZoologyTrinity College DublinDublinIreland
| | - R D Cousens
- Department of Plant SciencesUniversity of CaliforniaDavisCAUSA
| | - S Graham
- School of Social SciencesThe University of New South WalesSydneyNSWAustralia
| | - N R Jordan
- Agronomy & Plant Genetics DepartmentUniversity of MinnesotaSt. PaulMNUSA
| | - A Lawton‐Rauh
- Department of Genetics and BiochemistryClemson UniversityClemsonSCUSA
| | | | - M B Mesgaran
- Department of Plant SciencesUniversity of CaliforniaDavisCAUSA
| | - M Schut
- Knowledge, Technology and Innovation GroupWageningen UniversityWageningenthe Netherlands
- International Institute of Tropical Agriculture (IITA)KigaliRwanda
| | - J Shaw
- School of Biological SciencesThe University of QueenslandBrisbaneQldAustralia
| | - J Storkey
- Rothamsted ResearchBiointeractions & Crop Protection DepartmentHarpendenHertfordshireUK
| | - B Baraibar
- Plant Sciences DepartmentPenn State UniversityUniversity ParkPAUSA
| | - R S Baucom
- Department of Ecology and Evolutionary BiologyUniversity of MichiganAnn ArborMIUSA
| | - M Chalak
- School of Agricultural and Resource EconomicsCentre for Environmental Economics & PolicyUniversity of Western AustraliaCrawleyWAAustralia
| | - D Z Childs
- Department of Animal and Plant SciencesUniversity of SheffieldSheffieldUK
| | - S Christensen
- Department of Plant and Environmental SciencesUniversity of CopenhagenFrederiksbergDenmark
| | - H Eizenberg
- Department of Plant Pathology and Weed ResearchNewe Ya'ar Research CenterAgricultural Research Organization (ARO)Ramat YishayIsrael
| | | | - K French
- School of Biological SciencesUniversity of WollongongWollongongNSWAustralia
| | - M Harsch
- Department of BiologyUniversity of WashingtonSeattleWAUSA
| | - S Heijting
- Wageningen University and ResearchLelystadthe Netherlands
| | - L Harrison
- Environment DepartmentUniversity of YorkYorkUK
| | - D Loddo
- Institute of Agro‐environmental and forest BiologyNational Research Council (IBAF‐CNR)LegnaroItaly
| | - M Macel
- Molecular Interaction EcologyRadboud University NijmegenNijmegenthe Netherlands
| | | | - A Merotto
- Graduate Group in Plant ScienceSchool of AgricultureFederal University of Rio Grande do Sul (UFRGS)Porto AlegreBrazil
| | - D Mortensen
- Department of Ecology and Evolutionary BiologyUniversity of MichiganAnn ArborMIUSA
| | - J Necajeva
- Department of Plant PhysiologyFaculty of BiologyUniversity of LatviaRigaLatvia
| | - D A Peltzer
- Ecosystem Processes and Global ChangeLandcare ResearchLincolnNew Zealand
| | - J Recasens
- Horticulture, Botany and Landscaping DepartmentAgrotecnio, ETSEAUniversitat de LleidaLleidaSpain
| | - M Renton
- Schools of Biological Sciences & Agriculture and EnvironmentAustralian Herbicide Resistance Initiative and Institute of AgricultureThe University of Western AustraliaCrawleyWAAustralia
| | - M Riemens
- Environment DepartmentUniversity of YorkYorkUK
| | - M Sønderskov
- Department of AgroecologyAarhus UniversityFlakkebjergDenmark
| | - M Williams
- Michael Williams & Associates Pty LtdNatural resource Management Facilitators and StrategistsSydneyNSWAustralia
| | | |
Collapse
|
36
|
Buck DL, Christiansen CF, Christensen S, Møller MH. Out-of-hours intensive care unit admission and 90-day mortality: a Danish nationwide cohort study. Acta Anaesthesiol Scand 2018; 62:974-982. [PMID: 29602190 DOI: 10.1111/aas.13119] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 02/25/2018] [Accepted: 02/28/2018] [Indexed: 12/29/2022]
Abstract
BACKGROUND Mortality rates in critically ill adult patients admitted to the intensive care unit (ICU) remains high, and numerous patient- and disease-related adverse prognostic factors have been identified. In recent years, studies in a variety of emergency conditions suggested that outcome is dependent on the time of hospital admission. The importance of out-of-hours admission to the ICU has been sparsely evaluated and with ambiguous findings. We assessed the association between out-of-hours (16:00 to 07:00) and weekend admission to the ICU, respectively, and 90-day mortality in a nationwide cohort. METHODS We included all Danish adult patients admitted to the ICU between 1 January 2011 and 30 June 2014, with an ICU stay > 24 h. The crude and adjusted association between out-of-hours and weekend admission and 90-day mortality was assessed (odds ratio (ORs) with 95% confidence intervals (CI)). RESULTS A total of 44,797 patients were included, 53.3% were admitted out-of-hours, and 22.6% during weekends. Median age was 67 years (interquartile range (IQR) 55-76), and median SAPS II was 42 (IQR 30-54). Patients admitted in-hours vs. out-of-hours displayed a 90-day mortality rate of 41.0% vs. 44.2%. The adjusted association (OR with 95% CI) between out-of-hours admission and 90-day mortality was 1.07 (1.02-1.11), and the adjusted association (OR with 95% CI) between weekend admission and 90-day mortality was 1.10 (1.05-1.15). CONCLUSION This nationwide study suggests that critically ill adult patients admitted to the ICU during weekends and out-of-hours, and with an ICU stay > 24 h are at slightly increased risk of mortality.
Collapse
Affiliation(s)
- D. L. Buck
- Department of Intensive Care, 4131; Copenhagen University Hospital Rigshospitalet; Copenhagen Denmark
| | - C. F. Christiansen
- Department of Clinical Epidemiology; Aarhus University Hospital; Aarhus Denmark
| | - S. Christensen
- Department of Anaesthesiology and Intensive Care; Aarhus University Hospital; Aarhus Denmark
| | - M. H. Møller
- Department of Intensive Care, 4131; Copenhagen University Hospital Rigshospitalet; Copenhagen Denmark
| | | |
Collapse
|
37
|
von Felden J, Vermehren J, Schulze Zur Wiesch J, Sarrazin C, Christensen S. Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply. Aliment Pharmacol Ther 2018; 47:1550-1551. [PMID: 29878436 DOI: 10.1111/apt.14648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
Affiliation(s)
- J von Felden
- I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Divisions of Liver Diseases and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - J Vermehren
- Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt, Germany
| | - J Schulze Zur Wiesch
- I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,German Center for Infection Research (DZIF), Hamburg-site, Germany
| | - C Sarrazin
- Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt, Germany.,St. Josef's Hospital, Wiesbaden, Germany
| | | |
Collapse
|
38
|
von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2018. [PMID: 29536554 DOI: 10.1111/apt.14592] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Twelve weeks of the pangenotypic direct-acting antiviral (DAA) combination sofosbuvir/velpatasvir (SOF/VEL) was highly efficient in patients with hepatitis C virus (HCV) genotype 3 (GT3) infection in the ASTRAL-3 approval study. However, presence of resistance-associated substitutions (RASs) in the HCV nonstructural protein 5A (NS5A) was associated with lower treatment response. AIM To assess the efficacy and safety of SOF/VEL ± ribavirin (RBV) and the impact of NS5A RASs and RBV use on treatment outcome in HCV GT3 infection in a real-world setting. METHODS In this multicentre cohort study, GT3 patients from ten treatment centres across Germany were included. Sustained virological response was assessed 12 weeks after end-of-treatment (SVR12) in modified intention-to-treat (mITT) and per-protocol analysis (PP). NS5A RASs were tested by population-based sequencing. RESULTS A total of 293 GT3 patients were included. The median age was 48 years, 70% were male, 25.3% were cirrhotic, 9.2% were HCV/HIV co-infected and 21.8% were treatment-experienced, including 4.1% with DAA experience. Baseline NS5A RASs (Y93H, A30K, L31M) were detected in 11.2%. RBV was added in 5% of noncirrhotic and 58.9% of cirrhotic patients, respectively. SVR12 rates for SOF/VEL±RBV were 95.9% (mITT) and 99.5% (PP), respectively. Only 1 virological relapse occurred in a cirrhotic patient previously treated with SOF/RBV. No treatment-related major adverse events occurred. CONCLUSION Twelve weeks of SOL/VEL±RBV was safe and highly efficient in HCV GT3 across a diverse patient population. Baseline NS5A RASs were rarely observed and presence did not seem to impact SVR, regardless of the use of RBV.
Collapse
|
39
|
Guidet B, De Lange DW, Christensen S, Moreno R, Fjølner J, Dumas G, Flaatten H. Attitudes of physicians towards the care of critically ill elderly patients - a European survey. Acta Anaesthesiol Scand 2018; 62:207-219. [PMID: 29072306 DOI: 10.1111/aas.13021] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Revised: 08/18/2017] [Accepted: 10/04/2017] [Indexed: 11/30/2022]
Abstract
BACKGROUND Very elderly patients are one of the fastest growing population in ICUs worldwide. There are lots of controversies regarding admission, discharge of critically ill elderly patients, and also on treatment intensity during the ICU stay. As a consequence, practices vary considerably from one ICU to another. In that perspective, we collected opinions of experienced ICU physicians across Europe on statements focusing on patients older than 80. METHODS We sent an online questionnaire to the coordinator ICU physician of all participating ICUs of an recent European, observational study of Very old critically Ill Patients (VIP1 study). This questionnaire contained 12 statements about admission, triage, treatment and discharge of patients older than 80. RESULTS We received answers from 162 ICUs (52% of VIP1-study) spanning 20 different European countries. There were major disagreements between ICUs. Responders disagree that: there is clear evidence that ICU admission is beneficial (37%); seeking relatives' opinion is mandatory (17%); written triage guidelines must be available either at the hospital or ICU level (20%); level of care should be reduced (25%); a consultation of a geriatrician should be sought (34%) and a geriatrician should be part of the post-ICU trail (11%). The percentage of disagreement varies between statements and European regions. CONCLUSION There are major differences in the attitude of European ICU physicians on the admission, triage and treatment policies of patients older than 80 emphasizing the lack of consensus and poor level of evidence for most of the statements and outlining the need for future interventional studies.
Collapse
Affiliation(s)
- B. Guidet
- Hôpital Saint-Antoine; Service de Réanimation Médicale; Assistance Publique - Hôpitaux de Paris; Paris France
- UPMC Univ Paris 06; UMR_S 1136; Institut Pierre Louis d'Epidémiologie et de Santé Publique; Sorbonne Universités; Paris France
- UMR_S 1136; Institut Pierre Louis d'Epidémiologie et de Santé Publique; INSERM; Paris France
| | - D. W. De Lange
- Department of Intensive Care Medicine; University Medical Center; Utrecht The Netherlands
| | - S. Christensen
- Department of Anaesthesiology and Intensive Care; Aarhus University Hospital; Aarhus N Denmark
| | - R. Moreno
- Unidade de Cuidados Intensivos Neurocríticos; Hospital de São José; Centro Hospitalar de Lisboa Central; Lisbon Portugal
| | - J. Fjølner
- Department of Anaesthesiology and Intensive Care; Aarhus University Hospital; Aarhus N Denmark
| | - G. Dumas
- Hôpital Saint-Antoine; Service de Réanimation Médicale; Assistance Publique - Hôpitaux de Paris; Paris France
- UPMC Univ Paris 06; UMR_S 1136; Institut Pierre Louis d'Epidémiologie et de Santé Publique; Sorbonne Universités; Paris France
| | - H. Flaatten
- Department of Clinical Medicine; University of Bergen; Department of Anaesthesia and Intensive Care; Haukeland University Hospital; Bergen Norway
| |
Collapse
|
40
|
Kresch MJ, Christensen S, Kurtz M, Lubin J. Improving handover between the transport team and neonatal intensive care unit staff in neonatal transports using the plan-do-study-act tool. J Neonatal Perinatal Med 2018; 10:301-306. [PMID: 28854507 DOI: 10.3233/npm-16111] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVES The aim was to achieve 100% effective handover from the critical care transport team to the neonatal intensive care unit (NICU) medical team. STUDY DESIGN All patients transferred from referring hospitals by the critical care transport team to the Level IV NICU were included. Data for each infant was collected prospectively. The percentage of transported patients for which medical team and nursing handover occurred was recorded. A quality improvement project was launched using the Plan-Do-Study-Act (PDSA) tool. We implemented several processes including call from the transport team before arrival and the completion of a transfer of care form on arrival to the NICU. The process measures and the outcome measure of completion of handover were monitored. Run charts of process measures and the outcome measure were analyzed. RESULTS Completion of medical handover increased from 95% (baseline) to 100% after 3 PDSA cycles and this has been maintained for 18 consecutive months. CONCLUSION Medical handover from the critical care transport team to the NICU medical staff has been achieved and sustained for all neonatal transports.
Collapse
Affiliation(s)
- M J Kresch
- Department of Pediatrics, Division of Newborn Medicine, Penn State Health Children's Hospital, Hershey, PA, USA
| | - S Christensen
- Department of Emergency Medicine, Division of Prehospital and Transport Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA
| | - M Kurtz
- Department of Emergency Medicine, Division of Prehospital and Transport Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA
| | - J Lubin
- Department of Emergency Medicine, Division of Prehospital and Transport Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA
| |
Collapse
|
41
|
Glasser JG, Nottingham JM, Durkin M, Haney ME, Christensen S, Stroman R, Hammett T. Case series with literature review: Surgical approach to megarectum and/or megasigmoid in children with unremitting constipation. Ann Med Surg (Lond) 2017; 26:24-29. [PMID: 29326815 PMCID: PMC5760313 DOI: 10.1016/j.amsu.2017.12.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Revised: 12/13/2017] [Accepted: 12/21/2017] [Indexed: 11/26/2022] Open
Abstract
Background The role of surgery in treating children with functional constipation (FC) is controversial, because of the efficacy of bowel management programs. This case series is comprised of failures: 43 children, spanning 25 years' practice, who had megarectosigmoid (MRS) and unremitting constipation. Purpose To determine whether these children were helped by surgery, and to contribute to formulating a standard of care for children with megarectum (MR) and/or redundancy of the sigmoid colon (MS) who fail medical management. Method We describe our selection criteria and the procedures we utilized – mucosal proctectomy and endorectal pull-through (MP) or sigmoidectomy (SE) with colorectal anastomosis at the peritoneal reflection. The internet (social media) allowed us to contact most of these patients and obtain extremely long follow-up data. Results 30/43 patients had MP and 13/43 had SE. Follow-up was obtained in 83% MP and 70% SE patients. 60% of MP and 78% of SE patients reported regular evacuations and no soiling. 20% MP patients had occasional urgency or soiling or episodic constipation. 12% MP and 22% SE patients required antegrade continence enemas (ACE) or scheduled cathartics and/or stool softeners. 4% MP had no appreciable benefit, frequent loose stools and soiling, presumably from encopresis. Conclusion MR is characterized by diminished sensation, poor compliance and defective contractility. Patients with MR do better with MP, which effectively removes the entire rectum versus SE, where normal caliber colon is anastomosed to MR at the peritoneal reflection; furthermore, MP reliably preserves continence; whereas total proctectomy (trans-anal or trans-abdominal) may cause incontinence. Intestinal peristalsis stagnates in a dilated segment. Megarectosigmoid (MRS) may present during infancy or later in life. It may occur in association with anorectal malformations or as an isolated abnormality. Unlike dilatation secondary to outlet dysfunction, MRS persists even after a diverting colostomy. MRS does not respond to bowel management programs. Intestinal peristalsis improves following extirpation of MRS.
Collapse
Affiliation(s)
- James G Glasser
- Department of Surgery and Pediatrics, University of South Alabama, School of Medicine, Attending Surgeon, Children's and Women's Hospital, Mobile, AL, 36604, USA
| | - James M Nottingham
- University of South Carolina School of Medicine, 2 Richland Medical Park, Suite 300, Columbia, SC, 29203, USA
| | | | | | | | | | | |
Collapse
|
42
|
Omaga CA, Carpio LD, Imperial JS, Daly NL, Gajewiak J, Flores MS, Espino SS, Christensen S, Filchakova OM, López-Vera E, Raghuraman S, Olivera BM, Concepcion GP. Structure and Biological Activity of a Turripeptide from Unedogemmula bisaya Venom. Biochemistry 2017; 56:6051-6060. [PMID: 29090914 DOI: 10.1021/acs.biochem.7b00485] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The turripeptide ubi3a was isolated from the venom of the marine gastropod Unedogemmula bisaya, family Turridae, by bioassay-guided purification; both native and synthetic ubi3a elicited prolonged tremors when injected intracranially into mice. The sequence of the peptide, DCCOCOAGAVRCRFACC-NH2 (O = 4-hydroxyproline) follows the framework III pattern for cysteines (CC-C-C-CC) in the M-superfamily of conopeptides. The three-dimensional structure determined by NMR spectroscopy indicated a disulfide connectivity that is not found in conopeptides with the cysteine framework III: C1-C4, C2-C6, C3-C5. The peptide inhibited the activity of the α9α10 nicotinic acetylcholine receptor with relatively low affinity (IC50, 10.2 μM). Initial Constellation Pharmacology data revealed an excitatory activity of ubi3a on a specific subset of mouse dorsal root ganglion neurons.
Collapse
Affiliation(s)
- Carla A Omaga
- Marine Science Institute, University of the Philippines , P. Velasquez Street, Diliman, Quezon City 1101, Philippines.,Department of Biology, University of Utah , 257S 1400 E, Salt Lake City, Utah 84112, United States.,Department of Chemistry, University of Utah , 315 1400 E, Salt Lake City, Utah 84112, United States
| | - Louie D Carpio
- Marine Science Institute, University of the Philippines , P. Velasquez Street, Diliman, Quezon City 1101, Philippines
| | - Julita S Imperial
- Department of Biology, University of Utah , 257S 1400 E, Salt Lake City, Utah 84112, United States
| | - Norelle L Daly
- Centre for Biodiscovery and Molecular Development of Therapeutics, James Cook University , Cairns, Queensland 4870, Australia
| | - Joanna Gajewiak
- Department of Biology, University of Utah , 257S 1400 E, Salt Lake City, Utah 84112, United States
| | - Malem S Flores
- Marine Science Institute, University of the Philippines , P. Velasquez Street, Diliman, Quezon City 1101, Philippines
| | - Samuel S Espino
- Department of Biology, University of Utah , 257S 1400 E, Salt Lake City, Utah 84112, United States.,Washington University School of Medicine , 660 South Euclid Avenue, St. Louis, Missouri 63110, United States
| | - Sean Christensen
- Department of Biology, University of Utah , 257S 1400 E, Salt Lake City, Utah 84112, United States
| | - Olena M Filchakova
- Department of Biology, University of Utah , 257S 1400 E, Salt Lake City, Utah 84112, United States.,Biology Department, School of Science and Technology, Nazarbayev University , Qabanbay Batyr Avenue 53, Astana 010000, Kazakhstan
| | - Estuardo López-Vera
- Department of Biology, University of Utah , 257S 1400 E, Salt Lake City, Utah 84112, United States.,Instituto de Ciencias del Mar y Limnologia, Universidad Nacional Autonoma de Mexico , 04510 Coyoacan, DF, Mexico
| | - Shrinivasan Raghuraman
- Department of Biology, University of Utah , 257S 1400 E, Salt Lake City, Utah 84112, United States
| | - Baldomero M Olivera
- Department of Biology, University of Utah , 257S 1400 E, Salt Lake City, Utah 84112, United States
| | - Gisela P Concepcion
- Marine Science Institute, University of the Philippines , P. Velasquez Street, Diliman, Quezon City 1101, Philippines
| |
Collapse
|
43
|
Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van Bömmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, König B, Hüppe D, Wedemeyer H. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat 2017; 24:840-849. [PMID: 28342229 DOI: 10.1111/jvh.12708] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Accepted: 02/16/2017] [Indexed: 12/13/2022]
Abstract
Real-world studies are relevant to complement clinical trials on novel antiviral therapies against chronic hepatitis C; however, clinical practice data are currently limited. This study investigated effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r)±dasabuvir (DSV)±ribavirin (RBV) for treatment of HCV genotype (GT) 1 and GT4 infection in a large real-world cohort. The German Hepatitis C Registry is an observational cohort study prospectively collecting clinical practice data on direct-acting antiviral therapies. Patients with GT1/4 infection treated with OBV/PTV/r±DSV±RBV were analysed. Effectiveness was assessed by sustained virologic response in 558 patients who reached post-treatment week 12 (SVR12). Safety is reported in 1017 patients who initiated treatment. Of the patients, 892 (88%) had GT1 and 125 (12%) had GT4 infection. Prior treatment experience and cirrhosis were reported in 598 (59%) and 228 (22%) patients, respectively. Overall, SVR12 (mITT) was 96% (486/505) in GT1- and 100% (53/53) in GT4 patients. SVR12 rates were high across subgroups including patients with cirrhosis (95%, 123/129), patients with moderate to severe renal impairment (100%, 34/34), and subgroups excluded from registrational trials like patients ≥70 years (96%, 64/67) and failures to prior protease inhibitor treatment (96%, 46/48). Adverse events (AEs) and serious AEs were reported in 52% (525/1017) and 2% (21/1017) of patients, respectively, and led to treatment discontinuation in 1.5% (15/1017) of patients. OBV/PTV/r±DSV±RBV was effective and generally well tolerated for treatment of HCV infection in clinical practice.
Collapse
Affiliation(s)
- T M Welzel
- Department of Medicine 1, University Hospital, J.W. Goethe University, Frankfurt am Main, Germany
| | - H Hinrichsen
- Gastroenterology-Hepatology Center Kiel, Kiel, Germany
| | - C Sarrazin
- Department of Medicine 1, University Hospital, J.W. Goethe University, Frankfurt am Main, Germany.,Medical Department II, Gastroenterology, Hepatology, Infectiology, St. Josefs-Hospital, Wiesbaden, Germany
| | - P Buggisch
- Liver Unit, Asklepios Clinic St. Georg, IFI-Institute, Hamburg, Germany
| | | | - S Christensen
- Center for Interdisciplinary Medicine (CIM), Münster, Germany
| | - T Berg
- Section of Hepatology, Clinic for Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany
| | - S Mauss
- Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
| | - G Teuber
- Private Practice, Frankfurt am Main, Germany
| | - K Stein
- Hepatologie - Magdeburg, Magdeburg, Germany
| | - K Deterding
- Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
| | - F van Bömmel
- Section of Hepatology, Clinic for Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany
| | - R Heyne
- Leberzentrum am Checkpoint Berlin, Berlin, Germany
| | - C John
- Private Practice for Internal Medicine, Berlin, Germany
| | - T Zimmermann
- Department of Medicine I, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
| | - T Lutz
- Infektiologikum, Frankfurt am Main, Germany
| | - E Schott
- Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - J Hettinger
- AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany
| | - H Kleine
- AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany
| | - B König
- AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany
| | - D Hüppe
- Center for Gastroenterology and Hepatology, Herne
| | - H Wedemeyer
- Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
| |
Collapse
|
44
|
Flaatten H, de Lange DW, Artigas A, Bin D, Moreno R, Christensen S, Joynt GM, Bagshaw SM, Sprung CL, Benoit D, Soares M, Guidet B. The status of intensive care medicine research and a future agenda for very old patients in the ICU. Intensive Care Med 2017; 43:1319-1328. [DOI: 10.1007/s00134-017-4718-z] [Citation(s) in RCA: 110] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2016] [Accepted: 02/08/2017] [Indexed: 02/01/2023]
|
45
|
Fjølner J, Greisen J, Jørgensen MRS, Terkelsen CJ, Ilkjaer LB, Hansen TM, Eiskjaer H, Christensen S, Gjedsted J. Extracorporeal cardiopulmonary resuscitation after out-of-hospital cardiac arrest in a Danish health region. Acta Anaesthesiol Scand 2017; 61:176-185. [PMID: 27935015 DOI: 10.1111/aas.12843] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Revised: 11/06/2016] [Accepted: 11/11/2016] [Indexed: 01/07/2023]
Abstract
BACKGROUND Extracorporeal Cardiopulmonary Resuscitation (ECPR) has emerged as a feasible rescue therapy for refractory, normothermic out-of-hospital cardiac arrest (OHCA). Reported survival rates vary and comparison between studies is hampered by heterogeneous study populations, differences in bystander intervention and in pre-hospital emergency service organisation. We aimed to describe the first experiences, treatment details, complications and outcome with ECPR for OHCA in a Danish health region. METHODS Retrospective study of adult patients admitted at Aarhus University Hospital, Denmark between 1 January 2011 and 1 July 2015 with witnessed, refractory, normothermic OHCA treated with ECPR. OHCA was managed with pre-hospital advanced airway management and mechanical chest compression during transport. Relevant pre-hospital and in-hospital data were collected with special focus on low-flow time and ECPR duration. Survival to hospital discharge with Cerebral Performance Category (CPC) of 1 and 2 at hospital discharge was the primary endpoint. RESULTS Twenty-one patients were included. Median pre-hospital low-flow time was 54 min [range 5-100] and median total low-flow time was 121 min [range 55-192]. Seven patients survived (33%). Survivors had a CPC score of 1 or 2 at hospital discharge. Five survivors had a shockable initial rhythm. In all survivors coronary occlusion was the presumed cause of cardiac arrest. CONCLUSION Extracorporeal cardiopulmonary resuscitation is feasible as a rescue therapy in normothermic refractory OHCA in highly selected patients. Low-flow time was longer than previously reported. Survival with favourable neurological outcome is possible despite prolonged low-flow duration.
Collapse
Affiliation(s)
- J. Fjølner
- Department of Anaesthesia and Intensive Care; Head & Heart Centre; Aarhus University Hospital; Aarhus N Denmark
- Department of Clinical Medicine; Aarhus University; Aarhus N Denmark
| | - J. Greisen
- Department of Anaesthesia and Intensive Care; Head & Heart Centre; Aarhus University Hospital; Aarhus N Denmark
- Department of Clinical Medicine; Aarhus University; Aarhus N Denmark
| | - M. R. S. Jørgensen
- Department of Anaesthesia and Intensive Care; Head & Heart Centre; Aarhus University Hospital; Aarhus N Denmark
| | - C. J. Terkelsen
- Department of Cardiology; Head & Heart Centre; Aarhus University Hospital; Aarhus N Denmark
- Department of Clinical Medicine; Aarhus University; Aarhus N Denmark
| | - L. B. Ilkjaer
- Department of Cardiothoracic and Vascular Surgery; Head & Heart Centre; Aarhus University Hospital; Aarhus N Denmark
| | - T. M. Hansen
- Danish Air Ambulance; Department of Pre-hospital Medical Services; Aarhus N Denmark
| | - H. Eiskjaer
- Department of Cardiology; Head & Heart Centre; Aarhus University Hospital; Aarhus N Denmark
- Department of Clinical Medicine; Aarhus University; Aarhus N Denmark
| | - S. Christensen
- Department of Anaesthesia and Intensive Care; Head & Heart Centre; Aarhus University Hospital; Aarhus N Denmark
- Department of Clinical Medicine; Aarhus University; Aarhus N Denmark
| | - J. Gjedsted
- Department of Anaesthesia and Intensive Care; Head & Heart Centre; Aarhus University Hospital; Aarhus N Denmark
- Department of Clinical Medicine; Aarhus University; Aarhus N Denmark
| |
Collapse
|
46
|
Norekvål T, Fålun N, Mathisen L, Tollefsen S, Hiller A, Christensen S, Hjellestad B, Mowinckel N, Elstad N. 1247: A Need for a Specialisation in Cardiovascular Nursing? A National Survey Amongst Employers and Practitioners in Norway. Eur J Cardiovasc Nurs 2016. [DOI: 10.1177/147451510300200147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- T.M. Norekvål
- The board of National Society of Cardiac Nurses (NSF-LKS), Norway
- Haukeland University Hospital, Norway
| | - N. Fålun
- The board of National Society of Cardiac Nurses (NSF-LKS), Norway
- Haukeland University Hospital, Norway
| | | | | | - A. Hiller
- The board of National Society of Cardiac Nurses (NSF-LKS), Norway
- St. Olavs University Hospital, Norway
| | | | - B. Hjellestad
- The board of National Society of Cardiac Nurses (NSF-LKS), Norway
- Haukeland University Hospital, Norway
| | - N. Mowinckel
- The board of National Society of Cardiac Nurses (NSF-LKS), Norway
| | - N. Elstad
- The board of National Society of Cardiac Nurses (NSF-LKS), Norway
- St. Olavs University Hospital, Norway
| |
Collapse
|
47
|
Hüppe D, Buggisch P, Christensen S, Heiken H, Mauss S, Naumann U, Fischer C, Kleine H, Huelsenbeck J. Chronic hepatitis C patients prior to broad access to interferon-free treatments in Germany. Z Gastroenterol 2016; 54:740-7. [PMID: 27529525 DOI: 10.1055/s-0042-106731] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
In 2014, the first interferon-free treatment options for chronic Hepatitis C (CHC) became available in Europe introducing a new era of highly effective and well tolerated oral treatment options for CHC. The data from the cross-sectional study CURRENT-C highlights the epidemiological characteristics of patients with CHC in Germany. During the period that the study was conducted, the approval of the combination drugs for the treatment of CHC was imminent.Between June and November 2014, 1471 CHC-patients not receiving anti-HCV treatment were included nationwide in 40 German centers specializing in viral hepatitis. The mean age was 52.4 years with 41.2 % of the patients being female. Presumed route of infection in male patients was most frequently drug use (46.2 %) and blood products in females (22.8 %). The route of infection was unknown in 28.2 % of male and 43.1 % of female patients. Compared to male patients, female patients were older (55.6 vs. 50.1 years) and longer diagnosed with HCV (18 vs. 15 years). First language of the patients was most frequently German (72.2 %), followed by Russian (14.2 %), and Polish (2.9 %). HCV genotype (GT) 1 was found in 73.8 % (1a 29.0 %, 1b 38.4 %), GT2 in 3.5 %, GT3 in 18.3 %, GT4 in 4.2 %, GT5 in 0.2 %, and GT6 in 0.3 %. Liver cirrhosis was diagnosed in 15.7 % of the patients (17.1 % male, 13.7 % female). 43.2 % of the patients had already received HCV treatment, most frequently dual therapy with pegIFN + RBV (75.8 %) or triple therapy with telaprevir or boceprevir (20.3 %). Compared to treatment-naïve patients, pretreated HCV patients were older (55.1 vs. 50.3 years) and more frequently had liver cirrhosis as clinical diagnosis (22.2 % vs. 10.8 %). Patients scheduled for HCV treatment within the next 3 months had higher rates of pre-treatment (49.4 % vs. 37.0 %), and liver cirrhosis (21.4 % vs. 10.0 %).Compared to epidemiological data of Hüppe et al. 1 from 2003 to 2006, Klass et al. 2 stated in 2012 in a comparable setting that the German CHC population were older and had more advanced liver disease. The current data seem to support this ongoing trend towards more difficult to treat patients with an urgent need for new treatment options.
Collapse
Affiliation(s)
- D Hüppe
- Gastroenterologische Gemeinschaftspraxis, Herne, Germany
| | | | - S Christensen
- Center for Interdisciplinary Medicine, Muenster, Germany
| | - H Heiken
- Internistische Gemeinschaftspraxis, Hannover, Germany
| | - S Mauss
- Center for HIV and Hepatogastroenterology, Duesseldorf, Germany
| | - U Naumann
- Praxiszentrum Kaiserdamm, Berlin, Germany
| | - C Fischer
- Consultant in Medical Affairs and Market Access/HEOR, Munich, Germany
| | - H Kleine
- Medical HCV, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany
| | - J Huelsenbeck
- Medical HCV, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany
| |
Collapse
|
48
|
Abstract
Postoperative pain management in laboratory animals is important for animal welfare and required under law in many countries. Frequent injection of analgesics to rodents after surgery is stressful for the animals and labour-intensive for animal care personnel. An alternative dosing scheme such as administration of analgesics in the drinking water would be desirable. However, the efficacy of a chronic oral analgesic treatment via this route has not yet been documented. This study investigated the antinociceptive efficacy of buprenorphine administered ad libitum via the drinking water of laboratory rats. The antinociceptive efficacy of buprenorphine in drinking water was compared with repeated subcutaneous injections. A comparison was also made between buprenorphine in drinking water and the combination of one single subcutaneous injection of buprenorphine followed by buprenorphine in drinking water. Antinociception was assessed by use of an analgesiometric model measuring the rats' latency time to withdrawal from a noxious heat stimulus applied to the plantar surface of the paw. Results revealed that buprenorphine in drinking water (0.056 mg/mL) induced significant increases in paw withdrawal latency times during a three-day period of administration with a maximal effect at 39 h after the start of buprenorphine administration. One single injection of buprenorphine (0.1 mg/kg s.c.) followed by buprenorphine in the drinking water (0.056 mg/mL) induced an earlier onset of antinociception than buprenorphine in drinking water alone. In contrast, buprenorphine (0.1 mg/kg s.c.) injected every 8 h over a period of three days did not result in significant increases in paw withdrawal latency times. In conclusion, our results suggest that one single subcutaneous injection of buprenorphine followed by buprenorphine in drinking water may be a viable treatment option for the relief of pain in laboratory rats, but at the doses used in this study in pain-free rats it was associated with a decrease in water intake and some behavioural changes.
Collapse
Affiliation(s)
- L Jessen
- Department of Pharmacology, The Danish University of Pharmaceutical Sciences, DK-2100, Copenhagen, Denmark.
| | | | | |
Collapse
|
49
|
Mercado J, Xu M, Norton K, Peckham D, Posakony J, Tarcha E, Bartron J, Brown M, Lustig K, Manelli L, Ghelardini C, Cheppudira B, Fowler M, Christensen S, McIntosh J, Iadonato S. (421) A novel, non-opioid, conesnail peptide-based analgesic as a therapeutic alternative for the treatment of chronic pain. The Journal of Pain 2016. [DOI: 10.1016/j.jpain.2016.01.398] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
50
|
Christensen J, Koch H, Frandsen R, Zoetmulder M, Arvastson L, Christensen S, Sorensen H, Jennum P. Sleep stability and transitions in patients with idiopathic REM sleep behavior disorder and patients with Parkinson's disease. Sleep Med 2015. [DOI: 10.1016/j.sleep.2015.02.1422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|